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ABSTRACT 
Canine idiopathic pulmonary fibrosis (CIPF) is a chronic interstitial lung disease of 
unknown origin mainly affecting West Highland white terriers (WHWT). It has no curative 
treatment. Differentiating CIPF from other chronic respiratory diseases is difficult. A 
measurable biomarker would be an important addition to diagnostics. CIPF shares many 
clinical features with human idiopathic pulmonary fibrosis (IPF), but the histopathological 
resemblance of the canine and human diseases has been unclear. 
We described the clinicopathological and diagnostic imaging findings in dogs with CIPF 
and compared them with those of healthy WHWTs. The most typical clinical signs were 
cough and exercise intolerance. Fine inspiratory crackles, “Velcro crackles”, were 
characteristic and an abdominal breathing pattern was often present. Despite being 
hypoxemic, the dogs were commonly bright and alert. Bronchointerstitial opacity was the 
most common radiographic finding. In high resolution computed tomography, ground glass 
opacity was a consistent feature, whereas honeycombing and traction bronchiectasis were 
less common. Bronchoalveolar lavage fluid (BALF) total cell count was elevated in CIPF 
and bronchial changes were often detected. 
We investigated the serum and BALF concentrations of two potential fibrosis 
biomarkers, endothelin-1 (ET-1) and procollagen type III amino terminal propeptide 
(PIIINP) in dogs with CIPF, chronic bronchitis (CB), eosinophilic bronchopneumopathy 
(EBP) and healthy dogs. Serum ET-1 was higher in dogs with CIPF than in healthy dogs, 
dogs with EBP or dogs with CB. BALF ET-1 was measurable only in dogs with CIPF. 
BALF PIIINP was higher in dogs with CIPF than in dogs with CB or healthy dogs, but not 
different from dogs with EBP. Serum PIIINP was not useful in evaluating respiratory 
diseases in dogs.  
We defined the histopathological lesions and their distribution in WHWTs with CIPF 
and compared them with those of two human interstitial lung diseases. The diseases chosen 
for comparison were human IPF, the histopathological pattern of which is known as usual 
interstitial pneumonia (UIP), and nonspecific interstitial pneumonia (NSIP), which is an 
important differential diagnosis of human IPF. A diffuse mature interstitial fibrosis of 
varying severity, resembling human NSIP, was seen in the lungs of all dogs with CIPF. The 
majority of CIPF dogs also had multifocal areas of accentuated subpleural and 
peribronchiolar fibrosis with occasional honeycombing and profound alveolar epithelial 
changes, reminiscent of human UIP. Interstitial fibroblastic foci, characteristic of UIP, were 
not seen in WHWTs. Severe pulmonary lesions were seen more often in the caudal than in 
the cranial lung lobes.  
In this thesis we provide a detailed description of the clinicopathologic and diagnostic 
imaging features of CIPF and present quantitative values for arterial blood gases and BALF 
cytology. Our results indicate that serum ET-1 and BALF PIIINP are elevated in dogs with 
CIPF and could differentiate CIPF from CB. We conclude that CIPF is histopathologically 
characterised by two types of interstitial fibrosis and shares features of both human UIP and 
NSIP.
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ABBREVIATIONS 
ABE acid base excess 
ALP alkaline phosphatase 
BAL bronchoalveolar lavage 
BALF bronchoalveolar lavage fluid 
CB chronic bronchitis 
CIPF canine idiopathic pulmonary fibrosis 
CK cytokeratin 
COPD chronic obstructive pulmonary disease 
CT computed tomography 
DAD diffuse alveolar damage 
EBP eosinophilic bronchopneumopathy 
ET-1 endothelin-1 
GGO ground glass opacity 
HE hematoxylin and eosin 
HCO3- bicarbonate 
HMW-CK high molecular weight cytokeratin 
HRCT high resolution computed tomography 
HU Hounsfield unit 
IHC immunohistochemistry 
IIP idiopathic interstitial pneumonia 
ILD interstitial lung disease 
IPF idiopathic pulmonary fibrosis 
IQ interquartile range 
NSIP nonspecific interstitial pneumonia 
P(A-a)O2 alveolar-arterial oxygen gradient 
PaCO2 partial pressure of arterial carbon dioxide 
PH pulmonary hypertension 
PaO2 partial pressure of arterial oxygen 
PCI pneumocyte type I 
PCII pneumocyte type II 
PIIINP procollagen type III amino terminal propeptide 
ROC receiving operating characteristic 
SD standard deviation 
SMA α-smooth muscle actin 
SP surfactant protein 
TCC total cell count 
TGF-β transforming growth factor β 
UIP usual interstitial pneumonia 
WHWT West Highland white terrier 
 1   INTRODUCTION 
Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease with no known 
cure. It is chronic, inevitably progressive and eventually leads to death. IPF is recognised in 
humans (Liebow, 1975) and in their animal companions, cats (Cohn et al., 2004; Williams 
et al., 2004) and dogs (Corcoran et al., 1999a; Lobetti et al., 2001; Norris et al., 2005). The 
term ‘canine IPF’ (CIPF) is used for this disease in dogs with a view to separating the human 
and canine diseases.  
CIPF affects mainly the West Highland white terrier (WHWT), a small, friendly but 
self-reliant white terrier breed originating from the Highlands of Scotland. It was also in 
Scotland that the systemic study of CIPF began. After conference reports of an emerging 
fibrosing pulmonary disease affecting dogs, Corcoran et al. (1999b) published a case report 
of a Staffordshire bull terrier with idiopathic pulmonary fibrosis. Shortly after this, the 
clinical and diagnostic features of a chronic pulmonary disease were described in 29 
WHWTs (Corcoran et al., 1999a). In 2001, Lobetti et al. (2001) provided another case series 
of a schipperke, a bull terrier and three Staffordshire bull terriers affected by chronic 
idiopathic pulmonary fibrosis, and a year later a case report of another WHWT with the 
disease was published by Webb and Armstrong (2002). After this, articles about CIPF 
focused on the histopathological features (Norris et al., 2005), findings in high resolution 
computed tomography (HRCT) (Johnson et al., 2005), concomitant pulmonary hypertension 
(PH) (Schober and Baade, 2006), surfactant protein (SP) C (Erikson et al., 2009), detailed 
clinical features (Corcoran et al., 2011), and outcome and prognostic factors (Lilja?Maula 
et al., 2014a). The most recent research brings new insight into the pathogenesis of the 
disease by investigating the transforming growth factor β (TGF-β) signalling pathway 
(Krafft et al., 2014; Lilja-Maula et al., 2014b; Lilja-Maula et al., 2014c), gene expression 
profiles (Krafft et al., 2013) and chemokine concentrations (Roels et al., 2015a; Roels et al., 
2015b).  
CIPF has striking similarities to human IPF. The key feature of both diseases is an 
abnormal accumulation of collagen in the lung parenchyma for no known reason (Raghu et 
al., 1985; Norris et al., 2005). In both humans and dogs, diseased individuals tend to be old, 
suffer from unexplained cough and exercise intolerance, and fine inspiratory crackles, so 
called “Velcro” crackles, are heard on lung auscultation. Neither humans nor dogs can be 
cured of the disease (Corcoran et al., 1999a; Raghu et al., 2011). In humans, IPF diagnosis 
usually signifies a worse prognosis than most cancers (Ross et al., 2010).  
Diagnosing CIPF poses a challenge for the veterinarian. CIPF is a diagnosis of exclusion 
and laborious examinations are needed to reach that diagnosis. Differentiating CIPF from 
its main differential diagnosis, chronic bronchitis (CB), is especially challenging. An 
accurate fibrosis biomarker available for clinical use would be of great help to the veterinary 
practitioner.    
Many aspects of CIPF warrant further investigation. One question at the centre of 
attention is the histopathological picture of CIPF and to what extent it resembles that of 
human IPF. This is especially important considering the potential role dogs could have as a 
spontaneous animal model of human IPF. Several animal models of induced pulmonary 
fibrosis have been developed, mainly in small rodents, to study new therapeutic agents and 
1   Introduction 
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to unravel the fibrotic pathways of human IPF, but the progression of the disease and the 
histopathological changes differ when compared to the spontaneous form (Moeller et al., 
2008; Wolters et al., 2014). A model of spontaneous disease is currently lacking. 
This thesis is aimed at further defining the clinical features of the disease, evaluating the 
use of two potential fibrosis biomarkers in CIPF diagnostics, and shedding light on the 
histopathological aspects of CIPF and how it compares to human disease.  
 
 2   REVIEW OF THE LITERATURE 
2.1   INTERSTITIAL LUNG DISEASE IN DOGS AND HUMANS 
CIPF and IPF belong to a large and heterogeneous group of interstitial lung diseases (ILDs). 
The term is synonymous with diffuse parenchymal lung diseases. ILDs are lung disorders 
in which the distal lung parenchyma is disrupted. The lung can be grossly divided into two 
functional parts, the parenchyma and the nonparenchyma. The parenchyma contains the 
delicate gas-exchange tissue whereas as the nonparenchyma contains the airways, vessels 
and coarser connective tissue components (Weibel, 1986). The parenchymal interstitium of 
the lung is an anatomical space outlined by the alveolar epithelial cell and capillary 
endothelial cell basement membrane. The lung interstitium contains the extracellular matrix 
of the lung, collagen components, noncollagenous proteins as well as a few interstitial cells 
such as tissue macrophages, fibroblasts and myofibroblasts (Cosgrove and Schwarz, 2011) 
(Fig. 1). 
 
 
Figure 1 Schematic illustration of the alveolus and surrounding interstitium. 
More than 200 ILDs are recognised in humans. The word “interstitial” in the term ILD is 
something of a misnomer, because many ILDs also affect the airways, parenchyma, 
vasculature and pleura. Although some ILDs are associated with known etiological factors 
such as inhaled agents, drugs, infections, radiation or systemic diseases such as connective 
tissue disease, the majority of ILDs have an unknown aetiology (Cushley et al., 1999; 
Demedts et al., 2001).  
Many fewer ILDs are recognised in dogs than in humans (Norris et al., 2002; Reinero 
and Cohn, 2007). In the veterinary literature, the most often reported ILD in the dog appears 
2   Review of the literature 
 
 
 
 
15 
to be eosinophilic bronchopneumopathy (EBP). EBP and CIPF have received much 
attention in research over the last decade. Only a little is known about the occurrence of 
other ILDs in dogs and it is mainly only single case reports that have been published. The 
other reported ILDs in dogs are bronchiolitis obliterans with organising pneumonia, 
pulmonary alveolar proteinosis, endogenous lipid pneumonia, silicosis and asbestosis 
(Schuster, 1931; Canfield et al., 1989; Silverstein et al., 2000; Norris et al., 2002). Syrjä et 
al. (2009) described a familial lung disease in dalmatian dogs clinically resembling acute 
respiratory distress syndrome but with histopathological changes more similar to human 
usual interstitial pneumonia (UIP). Because histopathological assessment of lung tissue is 
often required for ILD diagnosis, EBP being an exception, some ILDs in dogs are likely to 
go unnoticed (Norris et al., 2002; Reinero and Cohn, 2007).  
2.2   CANINE AND HUMAN IDIOPATHIC PULMONARY FIBROSIS  
2.2.1   CLASSIFICATION AND DEFINITION 
Idiopathic interstitial pneumonias (IIPs) in humans 
Hamman and Rich (1935) were the first to describe an unexplained fatal interstitial fibrosis 
in human patients. An interstitial lung disease more like the one now called  IPF began to 
be increasingly reported only after the 1950s (Cordier and Cottin, 2013). In those early 
reports, IPF was a broader term which gathered together a spectrum of fibrosing lung 
disorders. Later, the term ‘IIP’ was introduced and IPF was classified as an IIP disorder. 
The classification was based on histopathology (Katzenstein and Myers, 1998). The IIPs are 
a group of non-neoplastic disorders which result from damage to the lung parenchyma by 
varying patterns of inflammation and fibrosis (American Thoracic Society, European 
Respiratory Society, 2002). The most recent classification by the American Thoracic 
Society and European Respiratory Society distinguishes seven major IIPs, two rare IIPs and 
a set of unclassifiable cases. Major IIPs are grouped into chronic and fibrosing, smoking-
related and acute/subacute IIPs. The chronic and fibrosing IIPs are IPF and idiopathic 
nonspecific interstitial pneumonia (NSIP). IPF is the most common IIP affecting humans, 
and NSIP is the second most common. The IIP group is not identified as such in veterinary 
medicine. 
Definition of IPF and CIPF 
The most recent evidence-based consensus on diagnosis and management of human IPF 
was published in 2011. The consensus gives joint guidelines from the American Thoracic 
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Society, European Respiratory Society, Japanese Thoracic Society and Latin American 
Thoracic Association, and characterises human IPF as follows: 
 “IPF is defined as a specific form of chronic, progressive, fibrosing interstitial 
pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and 
associated with the histopathologic and/or radiologic pattern of usual interstitial 
pneumonia. The definition of IPF requires the exclusion of other forms of interstitial 
pneumonia including other interstitial pneumonias and ILD associated with environmental 
exposure, medication, or systemic disease.” (Raghu et al., 2011). 
In this definition, the term ‘usual interstitial pneumonia’ is the name used for the 
histopathological pattern of human IPF. 
In veterinary medicine, no consensus on diagnosis or management of CIPF exists. CIPF 
is also not the only term used to describe the disease. Other names include IPF, chronic IPF, 
chronic pulmonary fibrosis, canine pulmonary fibrosis, chronic pulmonary disease in 
WHWTs and ILD in WHWTs (Corcoran et al., 1999a; Lobetti et al., 2001; Webb and 
Armstrong, 2002; Norris et al., 2005; Schober and Baade, 2006; Erikson et al., 2009; 
Corcoran et al., 2011). On the whole, the disease refers to a chronic, progressive, fibrosing 
ILD of unknown cause, occurring mainly in WHWTs. There is no evidence that tissues 
other than the lung would be affected. The diagnosis is one of exclusion and the 
histopathological pattern has not been clearly defined. 
2.2.2   AETIOLOGY AND PATHOGENESIS  
Etiological hypotheses 
As the word “idiopathic” implies, the aetiology of CIPF is unknown and the 
pathophysiology is incompletely understood. In the same way, the aetiology of human IPF 
remains indefinable. Fortunately, research in the last decade has improved comprehension 
of the mechanisms, especially behind the human disease (Spagnolo et al., 2015a). An early 
hypothesis about the aetiology of human IPF suggested that an initial insult to the lung could 
activate a chronic inflammatory response. The ongoing inflammation would then lead to 
fibrosis. This idea has been buried: inflammation is not prominent in IPF, it does not seem 
to be required for the development of a fibrotic response, and anti-inflammatory therapy 
provides no benefit for human patients (Gross and Hunninghake, 2001; Selman et al., 2001).  
The current hypothesis for the aetiology of human IPF focuses on a repetitive insult to 
distal lung parenchyma followed by an aberrant wound healing process. This is supported 
by a histopathological feature very characteristic of UIP: both newly formed and old fibroses 
are seen in the same lung area (Harari and Caminati, 2010). It is not currently known, 
whether this is also a feature in dogs. 
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Alveolar epithelial cells and fibroblasts in normal wound healing 
Alveoli are lined by two distinct types of epithelial cells, type I alveolar epithelial cells, also 
called pneumocyte type I (PCI) cells and type II alveolar epithelial cells, also called 
pneumocyte type II (PCII) cells. PCI cells are thin cells that cover most of the alveolar wall, 
interface with capillaries and provide a surface for gas exchange. PCI cells are susceptible 
to injury. PCII cells are larger cuboidal cells located in the corners of the alveoli. PCII cells 
are multifunctional, in that they serve as progenitor cells for PCI cells, produce surfactant 
and interact with mesenchymal cells immediately beneath them. PCII cells are more 
resistant to injury (Selman and Pardo, 2006; Lopez, 2007) (Fig. 1).  
In normal wound healing, the restoration of an intact epithelium after an insult is crucial. 
When PCI cells are injured and sloughed off, the PCII cells undergo hyperplastic 
proliferation and cover the exposed basement membranes. Some PCII cells then undergo 
programmed cell death (apoptosis), whereas others differentiate into PCI cells, completing 
the alveolar repair (Selman and Pardo, 2006; Lopez, 2007). 
Fibroblasts are active, spindle-shaped mesenchymal-derived cells. They are very 
important in any wound healing process. In response to injury, the number of fibroblasts 
increases at the site of the lesion and some differentiate into myofibroblasts, which are 
specialised fibroblasts with contractile activity. Fibroblasts and myofibroblasts play a key 
role in regulating the extracellular matrix turnover by synthesising and degrading its 
components. During normal healing, the unnecessary fibroblasts and myofibroblasts 
undergo apoptosis, and normal structure and function is restored (Ackermann, 2007; Ross 
et al., 2010; King Jr et al., 2011b).  
 Wound healing gone wrong 
Abnormal re-epithelialization, increased epithelial cell death, decreased fibroblast-
myofibroblast apoptosis and progressive extracellular matrix accumulation are hallmarks of 
IPF in humans (Selman et al., 2001). In IPF, the alveolar epithelium has an abnormal 
morphology and function. There is a loss of PCI cells likely due to injury and increased 
apoptosis but the PCII cells seem incapable of restoring them. PCII cells appear in increased 
numbers and are hyperplastic (Selman and Pardo, 2006; King Jr et al., 2011b) . The alveolar 
epithelial cells are abnormally activated and secrete growth factors, such as TGF-β, and 
cytokines inducing fibroblast proliferation, migration and recruitment of fibroblast 
progenitor cells. The production of TGF-β also induces the transformation of epithelial cells 
into fibroblasts in a process called epithelial mesenchymal cell transition, and provokes the 
differentiation of fibroblasts to myofibroblasts (King Jr et al., 2011b). The myofibroblasts 
in the IPF lung seem to be resistant to apoptosis. These events lead to an abnormal 
accumulation of fibroblasts and myofibroblasts, and the exaggerated production of collagen 
and other extracellular matrix components leading to architectural distortion characteristic 
of IPF lung. 
Although the events discussed above have not been studied in detail in CIPF, there is 
evidence to support the idea that alveolar epithelium also plays a role in CIPF. Recently, 
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increased TGF-β signalling activity was detected in the lungs of WHWTs with CIPF. Both 
Krafft et al. (2014) and Lilja-Maula et al. (2014c) then demonstrated that the majority of 
TGF-β responsive cells were located in the aberrant alveolar epithelium. This result suggests 
that abnormally activated alveolar epithelium has a role in the pathogenesis of CIPF, just as 
it has in human IPF.   
Epidemiologic and genetic risk factors  
In dogs, no epidemiologic studies evaluating the risk factors of CIPF have been performed. 
In humans, vigorous research has revealed several potential epidemiologic risk factors for 
IPF. Increased risk of developing IPF is associated with cigarette smoking, exposure to 
environmental and occupational agents such as metal and animal dust, gastro-oesophageal 
reflux, possibly diabetes and chronic viral infections (Baumgartner et al., 1997; 
Baumgartner et al., 2000; Enomoto et al., 2003; Tang et al., 2003; Raghu et al., 2006; 
Gribbin et al., 2009).  In particular, herpesviruses have been suggested to contribute to the 
pathogenesis of IPF (Calabrese et al., 2013). A family history of IPF was shown to be the 
strongest risk factor for human IPF in a recent study (García-Sancho et al., 2011). Despite 
these findings, no unifying aetiological factor has been discovered (Kottmann et al., 2009).  
In dogs, the accumulation of diseased individuals within one breed suggests that CIPF 
has a strong hereditary background. To date, only one study has examined gene mutations 
in CIPF.  Erikson et al. (2009) analysed surfactant protein (SP) B and SP C from three dogs 
with CIPF. In one CIPF dog, a Tibetan terrier, the SP C was absent and a mutation in SFTPC 
exon was detected. 
In humans, there is a growing body of evidence suggesting that genetic mutations 
predispose individuals to the development of IPF, although the vast majority of IPF cases 
appear to be sporadic. The familial form of IPF accounts for less than 5% of all cases. 
Mutation in SP C, SP A and in aging-related telomerase genes as well as a potential 
susceptibility gene called ELMOD2 have been associated with familial IPF (Raghu et al., 
2011). Recently, a strong association was confirmed between mucin 5 B gene promoter 
polymorphism and both familial and sporadic IPF. Genes involved in host defence, cell to 
cell adhesion and DNA repair have also been shown to contribute to the risk of developing 
IPF (Seibold et al., 2011; Fingerlin et al. 2013). 
Human IPF and probably also CIPF are likely to be the end result of a complex puzzle 
of endogenous and exogenous risk factors. Both environmental insults and a specific genetic 
background are required the development of the disease.  
2   Review of the literature 
 
 
 
 
19 
2.2.3   CLINICAL DISEASE 
CIPF 
CIPF affects mainly WHWTs. Dogs of other breeds, mainly terriers, can occasionally be 
affected. In the veterinary literature, CIPF is also reported in Staffordshire bull terriers, cairn 
terriers, a Tibetan terrier, a schipperke and a bull terrier (Corcoran et al., 1999a; Corcoran 
et al., 1999b; Lobetti et al., 2001; Johnson et al., 2005; Erikson et al., 2009). 
Dogs tend to be middle-aged or old when they get sick. Corcoran et al. (1999a) reported 
a mean age of 9 years at the time of diagnosis in a study of 29 WHWTs with CIPF. In other 
published cases the age has varied from 3 to 16 years. Three of the four reported 
Staffordshire bull terriers with CIPF were relatively young, at 3-5 years of age (Lobetti et 
al., 2001).  
The incidence and prevalence of CIPF are not known and no estimations have been 
published.  Commonly dogs are already suffering from advanced CIPF when they are 
presented to the veterinarian for the first time. CIPF is a diagnosis of exclusion and thorough 
examinations are needed to reach that diagnosis. Histopathologic examination of the lung 
tissue is the golden standard for diagnosis, however, lung biopsies are seldom taken on 
living dogs due to their invasiveness, and a histopathologic examination is often only 
performed after the dog’s euthanasia (Heikkilä-Laurila and Rajamäki, 2014). 
The described clinical signs are cough, exercise intolerance, breathlessness, dyspnoea, 
cyanosis, tachypnoea and orthopnoea. The clinical signs develop slowly and the dog’s 
condition deteriorates progressively over months (Corcoran et al., 1999a; Lobetti et al., 
2001; Webb and Armstrong, 2002; Johnson et al., 2005; Erikson et al., 2009; Corcoran et 
al., 2011; Lilja?Maula et al., 2014a).  
Lung auscultation reveals diffuse, fine and distinctive inspiratory crackles and 
sometimes wheezes or rhonchi. No consistent abnormalities have been reported in blood 
values (Corcoran et al., 1999a). Arterial blood gas analysis can be used to estimate lung 
function as other lung function tests are not easily available in dogs. Quantitative arterial 
blood gas values have been published only recently in a limited number of dogs with CIPF 
(Lilja?Maula et al., 2014a). Elevation of serum C reactive protein is not associated with 
CIPF (Viitanen et al., 2014).  
In thoracic radiographs, a generalised interstitial to bronchointerstitial lung pattern is 
commonly detected, but the finding is not specific to CIPF. Additionally, mixed alveolar 
and predominantly bronchial patterns have been reported in association with CIPF. Right-
sided cardiac enlargement is present in some dogs indicating cor pulmonale (Corcoran et 
al., 1999a; Webb and Armstrong, 2002; Johnson et al., 2005). In human IPF, the emphasis 
of thoracic imaging has shifted from radiography to HRCT which is a much more sensitive 
imaging technique for detecting changes in the lung parenchyma. Johnson et al. (2005) 
studied HRCT findings in 10 dogs with CIPF using a classification scheme from human 
medicine adapted for use in dogs. Dogs with CIPF were found to have the same spectrum 
of HRCT changes as human patients with IPF. According to Johnson et al. (2005), GGO 
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appeared in early CIPF, whereas interstitial thickening, traction bronchiectasis and 
honeycombing became evident at a later stage.  
Bronchoscopy and bronchoalveolar lavage (BAL) provide important information about 
the respiratory tract. Mild to moderate inflammation, mucosal changes such as roughening 
and thickening, expiratory dynamic airway collapse and tracheal collapse have been 
observed in dogs with CIPF (Corcoran et al., 1999a; Corcoran et al., 2011). Based on 
bronchoscopic examination and HRCT findings, Corcoran et al. (2011) suggested that a 
subset of CIPF cases were more likely to suffer from a bronchial than an interstitial disease, 
however, this finding requires confirmation: the diseased lung tissue should be examined 
histopathologically in order to determine whether more prominent airway involvement 
indicates an alternative diagnosis. There is no report of quantitative BAL fluid (BALF) 
analysis in dogs with CIPF.  
PH is a well known complication in human patients with IPF. Schober and Baade (2006) 
investigated the use of Doppler echocardiography in predicting PH in WHWTs with CIPF. 
In their study more than 40% of the WHWTs with CIPF were found to suffer from PH. 
Lilja-Maula et al. (2014a) attempted to find prognostic markers which would help 
predict the course of CIPF. No prognostic markers could be identified. Repeated arterial 
blood gas measurement and possibly also the distance walked in a six minute walk test could 
be a means of monitoring disease progression in dogs. Repeated thoracic radiographs do not 
seem to be very useful, because the radiographic changes may not be related to the change 
in clinical condition.  
Most dogs with CIPF are treated with corticosteroids and bronchodilators, and some also 
with antibiotics. The concurrent use of azathioprine has been suggested as of additional 
benefit. There is, however, no proven benefit of the treatment (Corcoran et al., 1999a; 
Lobetti et al., 2001). No treatment trials have been performed on dogs with CIPF, and the 
published studies about CIPF in dogs have not been designed to evaluate any treatment 
effect. There are no reports of using pirfenidone or nintedanib in dogs. 
Although the dogs are usually already old when they get sick, CIPF still has a negative 
impact on their life expectancy. Diseased dogs have an almost five times higher risk of 
dying than unaffected dogs of the same age. The median survival time varies among 
individual dogs. A recent study reported a median survival time of 2.7 years from the onset 
of clinical signs and one year from the diagnosis. Dogs have been suggested to have both a 
slowly progressive disease course as well as a rapidly progressing one, which is in line with 
the progression of IPF in humans (Lilja?Maula et al., 2014a).  
Human IPF 
IPF affects elderly people. Commonly, IPF is diagnosed when patients are in their sixth or 
seventh decades and diagnosis in patients of less than 50 years of age is rare. Men seem to 
be more often affected than women (Raghu et al., 2011). The vast majority of IPF cases are 
sporadic, and familial form accounts for less than 5% of all cases. Clinically and 
histopathologically these two forms are indistinguishable, except that patients with familial 
form tend to be younger than those with sporadic disease (Hodgson et al., 2002).  
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Prevalence and incidence vary, depending on the study population, disease definition 
and study design. Incidence has been estimated to vary between 5-16 cases per 100,000 
persons, and the prevalence between 13-20 cases per 100,000 persons. For unknown 
reasons, the incidence of IPF is rising (Navaratnam et al., 2011). 
The symptoms are slowly progressive exercise induced dyspnoea and cough. Patients 
are hypoxemic and have restrictive impairment in pulmonary function tests. Fine, bibasilar, 
end-inspiratory so-called “Velcro” crackles are heard in more than 80% of patients. 
Polycythaemia is rare despite chronic hypoxemia. Thoracic radiographs show bilateral 
peripheral reticular opacities (American Thoracic Society, European Respiratory Society, 
2000). A UIP pattern in HRCT or in surgical lung biopsy is required for diagnosis. The UIP 
pattern in HRCT includes patchy areas of reticular changes with honeycombing and traction 
bronchiectasis located in basal and peripheral lung areas. Ground glass opacity (GGO) 
should not be extensive (Raghu et al., 2011). 
IPF has a poor prognosis. The median survival of patients is only 2.5-3.5 years after 
diagnosis (King Jr et al., 2011b). The natural history varies: a patient may have a slowly 
progressive disease, a stable disease with acute periods of worsening, or an accelerated 
disease (Raghu et al., 2011). Pharmacological treatment options are very limited and for a 
long time, lung transplantation was the only means to extend the survival of patients (Rosas 
and Kaminski, 2015). Recommended non-pharmacological therapies include long-term 
oxygen therapy and pulmonary rehabilitation (Raghu et al., 2011). The standard 
pharmacological treatment used to be a combination of prednisolone, azathioprine and 
acetylcysteine but it was found harmful in a recent study (Raghu et al., 2012).  Very recently, 
two novel antifibrotic agents have brought new hope to patients suffering from IPF. These 
agents, nintedanib and pirfenidone, have been shown to reduce disease progression and are 
now approved for the treatment of human IPF (King Jr et al., 2014; Richeldi et al., 2014). 
2.2.4   HISTOPATHOLOGY 
CIPF 
The histopathology of CIPF has previously been investigated only in a limited number of 
dogs. The results have been inconsistent, especially regarding the lesion pattern and the 
resemblance between pulmonary lesions in dogs and those described in human UIP.   
CIPF is characterised by interstitial fibrosis and an accumulation of collagen types I and 
III in the alveolar septa (Norris et al., 2005). Hyperplastic and abnormal PCII cells and 
squamous metaplasia have been reported in association with CIPF. Fibroblast foci are a key 
feature of human UIP, but whether they are a feature of CIPF remains unclear. A fibroblast 
focus is a subepithelial, convex-appearing aggregate of proliferating fibroblasts and 
myofibroblasts (Katzenstein et al., 2008). Erikson et al. (2009) described centres of 
proliferating fibroblasts, but in the study of Norris et al. (2005) no such centres could be 
detected. The fibrosis pattern in the study of Norris et al. (2005) more resembles the diffuse 
uniform interstitial fibrosis observed in human NSIP than the patchy and heterogeneous 
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fibrosis pattern characteristic of human UIP (Katzenstein et al., 2008). Corcoran et al. 
(1999a) and Erikson et al. (2009) describe a multifocal severe fibrosis, more similar to 
human UIP.  
UIP 
Unlike in dogs, in humans the histopathological pattern of IPF has a specific name: UIP. 
IPF is only used as a clinical term. The word “usual” indicates that the histopathological 
pattern is the most commonly observed. The word “pneumonia” refers to inflammation 
rather than infection (Dempsey et al., 2006). 
The key feature of human UIP is the heterogeneity of the lesions. Spatial heterogeneity 
means that areas of less affected or normal lung parenchyma alternate with patchy areas of 
very severe fibrosis, scarring and honeycomb changes. A honeycomb is a cystic, fibrotic 
airspace lined by bronchiolar epithelium often filled with mucin. It is a manifestation of 
scarring and architectural remodelling (Katzenstein et al., 2008). In addition to spatial 
heterogeneity, the fibrosis is also temporally heterogeneous:  Areas of old, collagen rich 
fibrosis and scattered, small areas of active fibroproliferation coexist in the same lung area. 
These areas of active fibroproliferation are called fibroblast foci. Fibroblast foci are located 
in the interstitium, and the fibroblasts and myofibroblasts composing the foci are arranged 
parallel to the alveolar septa. The presence of fibroblast foci indicates an active, ongoing 
fibrosis (Katzenstein and Myers, 1998; Katzenstein et al, 2008). Smooth muscle hyperplasia 
can be seen in areas of fibrosis. The intra-alveolar accumulation of macrophages is a 
common finding. Inflammation is usually mild to moderate and consists of interstitial 
infiltrates of lymphocytes, plasma cells and histiocytes associated with PCII hyperplasia. 
Fibrosis is distributed subpleurally, paraseptally and peripherally (Katzenstein and Myers, 
1998; American Thoracic Society, European Respiratory Society, 2000; American Thoracic 
Society, European Respiratory Society, 2002; Katzenstein et al., 2008).  
2.3   NONSPECIFIC INTERSTITIAL PNEUMONIA 
NSIP is a chronic and fibrosing IIP described in humans. Such a disease has not been 
described in dogs to date. As indicated by the name, the findings are nonspecific. NSIP was 
accepted as a distinct clinical entity only very recently (Travis et al., 2013).  
The prevalence and incidence of NSIP are unknown. Affected patients are on average a 
decade younger than those affected by IPF. The symptoms, cough and dyspnoea, start 
gradually. A typical HRCT finding is a bilateral GGO with irregular reticular changes and 
traction bronchiectasis. Unlike in IPF, honeycombing is uncommon and subpleural lung 
areas are spared (Kligerman et al., 2009; Travis et al., 2013).  
Many cases of NSIP are idiopathic, however, the histopathologic pattern of NSIP is also 
associated with a variety of conditions such as collagen vascular disease, hypersensitivity 
pneumonitis, drug reactions, dust exposure and familial pulmonary fibrosis (Travis et al., 
2013). 
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NSIP can be divided into two main histologic subtypes, fibrotic and cellular NSIP, the 
cellular form being much less common than the fibrotic form. The differentiation is based 
on the degree of inflammation and fibrosis present (Kligerman et al., 2009). The prognosis 
of NSIP varies and depends on the amount of fibrosis. The cellular form responds well to 
corticosteroids and the prognosis is excellent. Patients with fibrotic NSIP have a median 
survival of 6-14 years, which is still clearly better than that of IPF (Kim et al., 2006).   
Histopathologically NSIP is characterised by varying amounts of inflammation, and 
fibrosis with a uniform appearance. Honeycombing is not a feature and fibroblast foci are 
seen only occasionally, if at all (Katzenstein et al., 2008; Travis et al., 2008). 
2.4   CANINE CHRONIC BRONCHITIS 
CB is one the most common chronic respiratory diseases affecting dogs (McKiernan, 2000). 
It is also the main differential diagnosis of CIPF (Corcoran et al., 1999a). CB is 
characterised by chronic inflammation of the airways, thickening of the bronchial walls and 
mucus hypersecretion. The key feature is a chronic, inexplicable cough occurring on most 
days in two consecutive months in the preceding year (Pirie and Wheeldon, 1976).  
The aetiology of the disease is poorly understood, but inhaled environmental irritants, 
tobacco smoke, low-grade infection, ongoing inflammation and genetic defects are 
suggested to play a role (McKiernan, 2000; Kuehn, 2004).  
CB mainly affects middle-aged to older small breed dogs, such as terriers, but bigger 
dogs can also be affected (Pirie and Wheeldon, 1976; Padrid et al., 1990). In addition to a 
cough, the affected dogs may also suffer from exercise intolerance, expiratory dyspnoea and 
even syncopes (Kuehn, 2004; Rozanski, 2014).  
CB is diagnosed by ruling out other chronic cardiac and respiratory diseases. Thoracic 
auscultation may reveal bronchovesicular sounds, crackles or wheezes but can also be 
unremarkable (McKiernan, 2000, Kuehn, 2004). Thoracic radiographs typically show 
thickening of the bronchial walls but can also be normal (Padrid et al., 1990; Mantis et al., 
1998). Computed tomography (CT) findings reported are bronchiectasis, bronchial wall 
thickening, ground glass opacity and peribronchiolar thickening (Szabo et al., 2015). 
Bronchoscopic changes include excessive mucus in the airways, hyperemic mucosal 
membranes and an irregular or polypoid appearance of the mucosa. Dogs may also show a 
partial collapse of the bronchi. In BALF, neutrophils are commonly increased (Padrid et al., 
1990; Rozanski, 2014).  
CB can lead to hypoxemia. In a previous study of 18 dogs with CB, 40% of the dogs 
were reported to be hypoxemic. The mean partial pressure or arterial oxygen (PaO2) was 84 
mmHg and it ranged from 67 to 110 mmHg before treatment was instituted (Padrid et al., 
1990). 
Similarly to CIPF, CB is an incurable disease, however, in many dogs the disease 
progression and the clinical signs can be controlled by glucocorticoid therapy which 
alleviates the airway inflammation. Bronchodilators may be of benefit for some individuals 
although they may not improve arterial blood oxygen values (Padrid et al., 1990; Rozanski, 
2014). 
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2.5   CANINE EOSINOPHILIC BRONCHOPNEUMOPATHY 
EBP is characterised by eosinophilic inflammation of the airways and pulmonary 
parenchyma. The disease is also referred to as pulmonary eosinophilia and pulmonary 
infiltration with eosinophils (Corcoran et al., 1991; Clercx et al., 2000; Rajamäki et al., 
2002). The cause for these eosinophilic infiltrations remains incompletely understood. 
Immunologic hypersensitivity to aeroallergens with a T helper 2 dominant immune response 
has been suggested (Clercx et al., 2002; Peeters et al., 2005). The diagnosis relies on 
documenting eosinophilic inflammation in BALF or bronchial biopsies, and ruling out 
known causes of eosinophilia (Clercx and Peeters, 2007). 
Unlike CIPF and CB, EBP usually affects young adult dogs. Siberian huskies and 
Alaskan malamutes seem to be predisposed, but a dog of any breed and size can be affected. 
Female dogs are affected more often than male dogs (Clercx and Peeters, 2007).  
Most dogs cough. Gagging, retching, exercise intolerance, dyspnoea, sneezing and nasal 
discharge can accompany the cough. Thoracic auscultation often reveals increased lung 
sounds, wheezes or crackles, but it can also be normal. In thoracic radiographs, moderate to 
severe bronchointerstitial pattern, peribronchial cuffing, alveolar infiltrates and 
bronchiectasis can be present (Corcoran et al., 1991; Clercx et al., 2000; Rajamäki et al., 
2002). A recent study looked into the CT images of EBP dogs and reported pulmonary 
parenchymal abnormalities, bronchial wall thickening, plugging of the bronchial lumen, 
bronchiectasis, pulmonary nodules and lymphadenopathy (Mesquita et al., 2015). In 
bronchoscopy, an increased amount of yellow to green or blood-tinged mucus, thickened 
mucosa with an irregular appearance, hyperaemia and sometimes expiratory airway closure 
can be observed (Clercx and Peeters, 2007). In addition to BALF eosinophilia, 
approximately 50% of dogs also have eosinophilia of the peripheral blood. Hypoxemia can 
be present, but appears not to be very common (Rajamäki et al., 2002).  
The hallmark of EBP treatment is glucocorticoid therapy. Some dogs are cured, whereas 
in other dogs relapses may occur after discontinuation of treatment. The general prognosis 
is good (Clercx et al., 2000; Rajamäki et al., 2002).  
2.6   BIOMARKERS OF CIPF 
As already mentioned, diagnosing CIPF requires extensive diagnostic work, but 
differentiating CIPF from CB or other chronic lung diseases can remain a challenge for the 
veterinarian. It is especially challenging to diagnose CIPF in its early phase when signs and 
findings are likely to be subtle. A fibrosis biomarker could therefore be helpful in resolving 
dilemmas related to diagnostics.  
A biological marker (biomarker) is any substance or feature that can be objectively 
measured and quantified from an individual, or from biological fluids, tissues, or from an 
individual themselves and serves as an indicator of normal biological or pathogenic 
processes (Atkinson et al., 2001).  A good biomarker is sensitive and specific, easily 
obtained and practical to use (Atkinson et al., 2001; Louhelainen et al., 2008; Ley et al., 
2014). An ideal biomarker would also have prognostic value and could help in uncovering 
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some of the pathomechanisms of the disease.  At the moment there are several candidate 
biomarkers for human IPF, but none has an established role in clinical practice (Ley et al., 
2014).  
Biomarker research in CIPF 
In dogs, different investigational approaches have been used in an attempt to identify 
potential biomarkers and to gain insight into the pathomechanisms of CIPF. We previously 
demonstrated by zymography that CIPF dogs had enhanced gelatinolytic activity in BALF. 
Matrix metalloproteinase -2 and -9 activities were higher than in dogs with CB (Heikkilä et 
al., 2011). Lilja-Maula et al. (2013) made a comparison of BALF proteomes between dogs 
with CIPF, CB and healthy dogs. The proteomic changes were similar in CIPF and CB dogs 
and no CIPF-specific proteins were identified. Activin B, a cytokine of the TGF-β family, 
was then detected in the BALF of WHWTs with CIPF suffering from acute exacerbation of 
the disease. Activin B might be a marker of alveolar epithelial damage in CIPF, but further 
research is needed to confirm this (Lilja-Maula et al., 2014b). Krafft et al. (2013) 
investigated the pulmonary gene expression from lung samples of dogs with CIPF and 
healthy control dogs by microarray analysis. A quantitative reverse transcriptase PCR 
analysis confirmed the change of expression for genes coding chemokine (C-C) ligand 
(CCL) 2, CCL7, chemokine (C-X-C) ligand 8 (CXCL8), CXCL14, fibroblast activation 
protein and the palate, lung and nasal associated protein (Krafft et al., 2013). Roels et al. 
(2015b) showed that serum and BALF CCL2 concentration and BALF CXCL8 
concentration were higher in WHWTs with CIPF than in healthy WHWTs. Serum CXCL8 
concentration was also higher in healthy WHWTs than in healthy dogs of other breeds 
(Roels et al., 2015a). Krafft et al. (2014) reported that the serum concentration of TGF-β1 
was elevated in WHWTs with CIPF. The concentration was also higher in healthy WHWTs 
when compared with healthy dogs of all other investigated breeds except the Scottish terrier.  
These results suggest that the chemokines CCL2 and CXCL8 and the profibrotic 
cytokine TGF-β1 might be potential biomarkers of CIPF. Because CXCL8 and TGF-β1 are 
elevated in both healthy and sick WHWTs but not in dogs of other breeds, these markers 
could also be related to the breed predisposition of WHWTs to CIPF (Roels et al., 2015a; 
Roels et al., 2015b). 
2.6.1   ENDOTHELIN-1 
Endothelin-1 (ET-1) is a vasoactive, proinflammatory and profibrotic peptide. It is a key 
mediator of fibrosis and involved in the pathogenesis of human IPF. ET-1 is the most 
abundant of the three isoforms of the endothelin family. The highest ET-1 levels are found 
in the lung but ET-1 also circulates in the blood (Fagan et al., 2001). ET-1 is synthesised as 
an inactive form which is then processed to active ET-1.  Its secretion is regulated at 
transcriptional level. ET-1 binds to endothelin specific receptors located in various cells 
throughout the body (Ross et al., 2010; Swigris and Brown, 2010) (Fig. 2).  
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In a fibrotic lung, ET-1 orchestrates a wide variety of profibrotic and proinflammatory 
processes.  ET-1, for example, induces the production of TGF-β and other cytokines, has 
mitogenic effects on vascular and airway smooth muscle cells and fibroblasts, stimulates 
fibroblast chemotaxis, proliferation and collagen production, decreases collagen 
degradation, mediates the epithelial to mesenchymal transition and the differentiation of 
fibroblasts into myofibroblasts (Teder and Noble, 2000; Fagan et al., 2001; Jain et al., 2007; 
Ross et al., 2010).  
Further evidence of the participation of ET-1 in fibrosis process comes from studies in 
which ET-1 action is blocked by its antagonist. A dual ET antagonist, bosentan, has been 
shown to attenuate lung collagen accumulation in a bleomycin induced rodent model of 
pulmonary fibrosis. Bosentan has shown some promise in the treatment of human IPF, but 
the results of the latest studies have been disappointing (King Jr et al., 2011a; Spagnolo et 
al., 2015b).  
 
Figure 2 Simplified illustration of endothelin-1 (ET-1) synthesis. In fibrotic lung, ET-1 is 
secreted by endothelial and alveolar epithelial cells, neutrophils, macrophages, 
fibroblasts and myofibroblasts. ET-1 is synthesised as a preprohormone which is 
processed to big ET-1 and finally to ET-1, a biologically active peptide of 21 amino 
acids. Synthesis is enhanced by various stimuli such as TGF-β and ET-1 itself, and 
inhibited by nitric oxide. ET-1 is not stored. Once secreted, its actions are mediated 
through ETA and ETB receptors (Fagan et al., 2001). 
ET-1 as a biomarker in dogs 
Commercially available immunoassays for measurement of human ET-1 have been 
validated for the use in dogs (Schellenberg et al., 2008). Mostly, ET-1 has been investigated 
as a cardiac biomarker. Blood ET-1 concentration is higher in dogs with cardiac disease or 
respiratory disease than in healthy dogs, and the concentration rises when cardiac or 
respiratory disease worsens (Tessier-Vetzel et al., 2006; Piantedosi et al., 2009). Higher 
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blood ET-1 concentration is detected in dogs with congestive heart failure compared to dogs 
with cardiac disease but no heart failure (Prošek et al., 2004). Blood ET-1 concentration can 
be used to differentiate dogs with dyspnoea due to heart failure from those with 
noncardiogenic dyspnoea (Prošek et al., 2007). An elevated blood ET-1 concentration is 
also detected in dogs with heartworm disease and in the canine model of ventilator-induced 
lung injury (Uchide and Saida, 2005; Lai et al., 2010). The concentration of the ET-1 
precursor, big ET-1, has also been investigated in dogs, and an increased blood big ET-1 
concentration is detected in dogs with chronic kidney disease, neoplastic disorders, cardiac 
diseases and PH (O'Sullivan et al., 2007; Rossi et al., 2013; Fukumoto et al., 2014). To the 
author’s knowledge, no study has evaluated the use of ET-1 concentration to distinguish 
between different respiratory diseases in dogs.  
ET-1 as a biomarker in humans  
Elevated ET-1 concentration in blood and BALF and enhanced tissue expression of ET-1 
are well documented in human patients with IPF (Giaid et al., 1993; Sofia et al., 1993; 
Uguccioni et al., 1995),  however, the rise in ET-1 is not specific to IPF and other lung 
diseases such as asthma, pneumonia, acute respiratory distress syndrome and sarcoidosis 
have also been associated with increases in blood or BALF ET-1 in humans (Sofia et al., 
1993; Letizia et al., 2001; Reichenberger et al., 2001; Gawlik et al., 2006).  
Most ET-1 studies have concentrated on the cardiovascular system (Teder and Noble, 
2000). ET-1 is known to be a very potent vasoconstrictor and high plasma concentration has 
been documented in PH and heart failure (Chester and Yacoub, 2014; Gottlieb et al., 2014). 
ET-1 concentration also increases with age (Komatsumoto and Nara, 1995).  
2.6.2   PROCOLLAGEN TYPE III AMINO TERMINAL PROPEPTIDE 
Collagens are the most abundant proteins in animals and major elements in the extracellular 
matrix. They are classified according to their function and structure. Type III collagen is 
one of the fibrillary collagens which provides tensile strength for connective tissues. During 
the synthesis of collagen type III, an amino terminal propeptide is proteolytically cleaved 
from the procollagen molecule to form mature collagen (Fig. 3). This propeptide, the 
procollagen type III amino terminal propeptide (PIIINP), is then released into extracellular 
fluid and circulation in proportion to the amount of collagen produced (Prockop et al., 1979; 
Patino et al., 2002; Kadler et al., 2007).  
PIIINP is measurable from various body fluids. Blood PIIINP concentration depends on 
the rate of its synthesis and can thus be used as a marker for enhanced collagen type III 
metabolism. In BALF, the levels of PIIINP are likely to represent the local production of 
collagen in the lung (Lammi et al., 1999).  
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Figure 3 Schematic illustration of procollagen molecule. After being secreted from the cell, 
amino (N) terminal and carboxy (C) terminal ends of the procollagen molecule are 
cleaved by proteases and a mature collagen monomer molecule is formed. The N-
terminal propeptide of procollagen type III is called PIIINP. 
PIIINP as a biomarker in dogs 
A radioimmunoassay for measuring PIIINP in BALF and serum has been validated in dogs 
(Schuller et al., 2006). Young, growing dogs have a higher serum and BALF PIIINP 
concentration than adult dogs. Cardiac diseases and chronic kidney disease do not seem to 
increase serum PIIINP concentration but collagen type III glomerulopathy is associated with 
increased values. High BALF PIIINP concentration was reported in a group of dogs with 
chronic bronchopneumopathy that consisted mainly of dogs with EBP (Schuller et al., 2006; 
Rortveit et al., 2013). As an abnormal accumulation of collagen types I and III in the 
pulmonary interstitium is a hallmark of CIPF (Raghu et al., 1985; Norris et al., 2005), 
PIIINP could be a useful indicator of the disease. PIIINP concentrations have not previously 
been investigated in dogs with CIPF. 
PIIINP as a biomarker in humans 
An elevation of PIIINP concentration is detected in the blood and BALF of human patients 
with IPF (Harrison et al., 1993; Hiwatari et al., 1997; Lammi et al., 1999), however, other 
respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, 
sarcoidosis, acute respiratory distress syndrome and infant bronchopulmonary dysplasia 
have also been associated with increased concentrations or enhanced expression of PIIINP 
in humans (Lammi et al., 1997; Meduri et al., 1998; Kaarteenaho?Wiik et al., 2004;  
Kanazawa and Yoshikawa, 2005; Harju et al., 2010).  
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Blood PIIINP concentration is also affected by a variety of disorders, other than lung 
diseases. Elevated blood PIIINP concentrations are also associated with growth in healthy 
young individuals (Lammi et al., 1999). 
 
 
 
 3   AIMS OF THE THESIS 
The objective of this thesis was to describe the clinico- and histopathological findings of 
CIPF and to determine the usefulness of two fibrosis biomarkers in its diagnosis.  
The detailed aims were as follows: 
 
1. To describe the clinical signs and findings of physical examination, blood 
and arterial blood gas analyses, radiography, HRCT, bronchoscopy and 
BALF cytology in WHWTs with CIPF and compare them with healthy 
control WHWTs (Study I). 
2. To analyse the concentration of ET-1 and PIIINP in the serum and BALF of 
dogs with CIPF, CB, EBP and healthy dogs, and to determine whether the 
concentration can be used to differentiate CIPF from other chronic 
respiratory diseases, namely CB and EBP, in dogs (Studies II and III).  
3. To define the histopathological lesions and their distribution in WHWTs 
with CIPF and to compare them with those of human UIP and NSIP (Study 
IV). 
 4   MATERIAL AND METHODS 
4.1   SELECTION OF DOGS AND DIAGNOSTIC CRITERIA 
4.1.1   DOGS WITH CIPF (STUDIES I, II, III) 
Fourteen privately owned WHWTs and one privately owned Scottish terrier with CIPF were 
prospectively recruited in the years 2007-2009. The dogs were diagnosed either at the 
Veterinary Teaching Hospital of the University of Helsinki, Finland, or at the Veterinary 
Teaching Hospital of the University of Liège, Belgium.   
The diagnostic evaluation of CIPF dogs consisted of history and physical examination 
(15/15), haematology (13/15), serum biochemistry (13/15), faecal examination (10/15), 
arterial blood gas analysis (11/15), thoracic radiography (13/15), echocardiography (13/15), 
HRCT (7/15), bronchoscopy and BAL (13/15). The CIPF diagnosis was later confirmed by 
histopathological examination of lung tissue in all dogs. Histopathology was performed 
either by M.J. Day as described in Study I, or by P. Syrjä, as described in detail in Section 
4.6. The signalment, the examinations performed on the individual dogs, and inclusion in 
the different studies of this dissertation are presented in Table 1.  
4.1.2   DOGS WITH CHRONIC BRONCHITIS (STUDIES II, III) 
Serum and BALF samples were collected from 22 dogs of various breeds with a diagnosis 
of CB. Samples were obtained in 2001-2008. Dogs with CB were seen either at the 
Veterinary Teaching Hospital of the University of Liège, or at the Veterinary Teaching 
Hospital of the University of Helsinki.   
Diagnosis of CB was based on clinical signs (chronic cough) and the findings of thoracic 
radiography, bronchoscopy and BALF analysis (Kuehn, 2004). Other chronic respiratory 
and cardiac diseases were excluded. The diagnostic investigation also included haematology 
(22/22), histopathological examination of bronchial mucosal biopsies (13/22), faecal 
examination (10/22), arterial blood gas analysis (5/22), echocardiography (5/22) and HRCT 
(2/22). The signalment, the examinations performed on the individual dogs, and inclusion 
in the different studies of this dissertation are presented in Table 2.  
4.1.3   DOGS WITH EOSINOPHILIC BRONCHOPNEUMOPATHY (STUDIES II, 
III) 
Serum and BALF samples were collected from 15 dogs of various breeds with a diagnosis 
of EBP. All the dogs were examined at the Veterinary Teaching Hospital of the University 
of Liège during years 2001-2009.  
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The diagnosis of EBP was based on clinical signs, eosinophilia in BALF or bronchial 
eosinophilic infiltration, and clinical response to glucocorticoids (Clercx and Peeters, 2007). 
Haematology (15/15), thoracic radiography (14/15), histopathological examination of 
bronchial mucosal biopsies (14/15) and either faecal examination (9/15) or therapeutic trial 
with fenbendazole (6/15) were performed. The signalment, the examinations performed on 
the individual dogs and inclusion in the different studies of this dissertation are presented in 
Table 3.  
4.1.4   HEALTHY CONTROL DOGS (STUDIES I, II, III) 
Fourteen clinically healthy privately owned older WHWTs were prospectively recruited at 
the Veterinary Teaching Hospital of the University of Helsinki in the years 2007-2009.  
To confirm their health status, the dogs underwent thorough clinical examinations: 
history and physical examination (14/14), haematology and serum biochemistry (14/14), 
faecal examination (14/14), arterial blood gas analysis (12/14), thoracic radiography 
(14/14), echocardiography (13/14), HRCT (11/14), and bronchoscopy and BAL (11/14). 
The serum and BALF samples of 21 healthy laboratory beagles were also collected 
during 2005-2008. The beagles were owned by the Faculty of Veterinary Medicine of the 
University of Liège or by the Faculty of Veterinary Medicine of the University of Helsinki.  
Physical examination, haematology, serum biochemistry, thoracic radiography and 
bronchoscopy with BAL were performed for all beagles. Arterial blood gas analysis was 
obtained from 12 of the 21 beagles. The signalment, the examinations performed on the 
individual dogs and inclusion in the different studies of this dissertation are presented in 
Table 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4   Material and methods 
 
 
 
 
33 
Table 1 CIPF dogs: signalment, clinicopathological examinations and  
                   inclusion in the studies of this doctoral dissertation. 
 signalment examinations inclusion in studies 
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1 F whwt 13 M + + + + + + + + + + + + + + + + 
2 F wtwt 12 F - - - - - + - + - - - + + - + + 
3 F whwt 12 M + + + + + + + + + + + + + + + + 
4 F whwt 10 F + + + + + + + + + - + + + + + + 
5 F whwt 12 M + - + + + + - + + + + + + + + + 
6 F whwt 14 f + + + + + + + + - - + + + - + - 
7 F whwt 12 M + + + + + + + + + - + + + + + + 
8 F whwt 11 F + + + + + + + + + + + + + + + + 
9 F whwt 14 M + + + + + + + + + - + + + + + + 
10* F whwt 14 M + + + + + + + + - - - - - - - + 
11 F whwt 15 M + - - - - + - + - - - + + - + + 
12 F whwt 11 f + + + + + + + + + + + + # + + + 
13 F whwt 12 f + + + + + + + + + - + + + + + + 
14 F whwt 13 F + + - + + - - + + - + - + + + + 
15 F whwt 8 M + + + + + - - + + - + - # + + + 
16 B Scottish 15 M + - - + - - - + + + + + # + + - 
17 F whwt 15 M + + + + + + - + - - - - - - - + 
18 A whwt n n n n n n n n n + - - - - - - - + 
19 B whwt n n n n n n n n n + - - - - - - - + 
20 N whwt n n n n n n n n n + - - - - - - - + 
In Chapter 5.1 of this dissertation, the clinicopathological analyses of 3 dogs were added to the results of 
Study I.  These dogs are denoted # in the Table 1. Dog No. 10, marked with asterisk (*), corresponds to the 
dog No.10 in Table 4 (see explanation in Chapter 4.2). 
ABG, arterial blood gases; A, Austria; BAL, bronchoalveolar lavage; B, Belgium; B ET-1, BAL fluid 
endothelin-1; B PIIINP, BAL fluid procollagen type III   terminal propeptide; echo, echocardiography; F, 
Finland or female; f, neutered female; histo, histological examination of lung tissue; HRCT, high resolution 
computed tomography; M, male; m, neutered male; n, not reported; N, the Netherlands; s ET-1, serum 
endothelin-1; Scottish, Scottish terrier; s PIIINP serum procollagen type III amino terminal propeptide; THX 
XR, thoracic radiography; v.blood, venous blood; whwt, West Highland white terrier. 
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Table 2 Dogs with chronic bronchitis: signalment, clinicopathological  
                   examinations and inclusion in the studies of this doctoral dissertation. 
 signalment examinations inclusion in studies 
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1 F shetl. 
sheepd. 
10 F + + - + + + + - - - + + - - + - 
2 F schipp-
erke 
14 M + + + + + + - - - - + + - - + - 
3 F labrador 11 M + + - + + + - - - - + + - - + - 
4 F cairn 9 f + + + + - + - - - - + + - - + - 
5 F shetl. 
sheepd. 
12 M + + + + + + + - - - + + - - + - 
6 B ir.setter 11 M + - + + - + - - + - - + - + + - 
7 B labrador 10 M + - - + - + - + + - + + - + + - 
8 B mixed 10 f + - + + - + - + - - - + - - + - 
9 B dachsh. 9 f + - + + - + - + + + + + - + + - 
10 B malinois 11 m + - + + - + - + + - - + - + + - 
11 B brittany 12 M + - - - - + - - - - - + - - + - 
12 B j. russell 7 f + - - + - + - + + - - + - + + - 
13 B tervueren 8 m + - + + - + - + - - - + - - + - 
14 B old engl. 
sheepd. 
9 M + - - + - + - + - - - + - - + - 
15 B mixed 4 f + - - + - + - + - - - + - - + - 
16 B dalma- 
tian 
9 F + - - + - + - + - - - + - - + - 
17 B beagle 6 F + - - + - + - + - - - + - - + - 
18 B brittany 11 F + - - + - + - + + + + + - + + - 
19 B dachsh. 12 M + - - + - + - + + + + + - + + - 
20 B yorkshire 1 F + - - + - + - - + + - - - + - - 
21 B mixed 2 F + - + + - + - - + - - - - + - - 
22 B dober- 
mann 
10 f + - + + - + - + + + - - - + - - 
ABG, arterial blood gases; BAL, bronchoalveolar lavage; B, Belgium; B ET-1, BAL fluid endothelin-1; B 
PIIINP, BAL fluid procollagen type III amino terminal propeptide; cairn terr., cairn terrier; dachsh., 
dachshund; echo, echocardiography; F, Finland or female; f, neutered female; histo BM, histological 
examination of bronchial mucosal biopsies; HRCT, high resolution computed tomography; ir.setter, Irish 
setter; j.russell, Jack Russell terrier; M, male; m, neutered male; old engl. sheepd., old English sheepdog; s 
ET-1, serum endothelin-1; shetl. sheepd., Shetland sheepdog; s PIIINP serum procollagen type III amino 
terminal propeptide; THX XR, thoracic radiography; v.blood, venous blood; yorkshire, Yorkshire terrier. 
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Table 3 Dogs with eosinophilic bronchopneumopathy: signalment,              
                   clinicopathological examinations and inclusion in the studies of this doctoral  
                   dissertation. 
 signalment examinations inclusion in studies 
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1 B whippet 5 M + - - - - + - - + - - + - + + - 
2 B mixed 12 M + - + + - + - + + - + + - + + - 
3 B mixed 7 M + - + + - + - + + - + + - + + - 
4 B mixed 7 F + - + + - + - + - - - + - - + - 
5 B fox terr. 8 f + - + + - + - + + - - + - + + - 
6 B cairn 11 F + - - + - + - + - - + + - - + - 
7 B husky 9 M + - + + - + - + - - + + - - + - 
8 B mixed 7 f + - + + - + - + - - - + - - + - 
9 B newfound 3 F + - + + - + - + - - - + - - + - 
10 B poodle 6 f + - + + - + - + - - - + - - + - 
11 B husky 1 M + - - + - + - + - - + + - - + - 
12 B j.russell 5 m + - - + - + - + - - + + - - + - 
13 B mixed 7 m + - + + - + - + - - + + - - + - 
14 B labrador 1 M + - - + - + - + + - - - - + - - 
15 B rottweil. 9 F + - - + - + - + + - - - - + - - 
ABG, arterial blood gases; BAL, bronchoalveolar lavage; B, Belgium; histo BM, B ET-1, BAL fluid 
endothelin-1; B PIIINP, BAL fluid procollagen type III amino terminal propeptide; cairn, cairn terrier; echo, 
echocardiography; F, female; f, neutered female; fox terr., fox terrier; histo BM, histological examination of 
bronchial mucosal biopsies; HRCT, high resolution computed tomography; j.russell, Jack Russell terrier; M, 
male; m, neutered male; newfound, Newfoundland; rottweil., rottweiler; s ET-1, serum endothelin-1; s PIIINP 
serum procollagen type III amino terminal propeptide; THX XR, thoracic radiography; v.blood, venous blood. 
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Table 4 Healthy control dogs: signalment, clinicopathological examinations  
                   and inclusion in the studies of this doctoral dissertation. 
 signalment examinations inclusion in studies 
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1 F whwt 6 F + + + + + + + - + - + + + + + - 
2 F whwt 4 m + + + + + + + - + - + + + + + - 
3 F whwt 9 M + + + + + + + - + + + + + + + - 
4 F whwt 12 F + + + + + + + - + + + + + + + + 
5 F whwt 11 f + - + + + + + - + - + + + + + - 
6 F whwt 8 F + + + + + + + - + + + + + + + - 
7 F whwt 10 f + + + + + + + - + + + + + + + - 
8 F whwt 3 f + + + + + + + - + - + + + + + - 
9 F whwt 9 F + + + + + + + - + + + + + + + - 
10* F whwt 14 m + + + + + + + - + - + + + + + - 
11 F whwt 11 m + + + + + + + - + - + - + + + - 
12 F whwt 14 F + + + + + - - - + - + - + + + - 
13 F whwt 10 M + + + + + - - - + - + - + + + - 
14 F whwt 8 f + - + + + - - - - - - - + - - - 
15 F whwt 2 M - - - - - - - + - - - - - - - + 
16 F whwt 6 F - - - - - - - + - - - - - - - + 
17 B beagle 3 M + - - + - + - - + - - - - + - - 
18 B beagle 6 F + - - + - + - - + - - - - + - - 
19 B beagle 7 F + - - + - + - - + - - - - + - - 
18 B beagle 5 M + - - + - + - - + - - - - + - - 
19 B beagle 8 M + - - + - + - - + - - - - + - - 
20 B beagle 8 F + - - + - + - - + - - - - + - - 
21 B beagle 8 F + - - + - + - - + - - - - + - - 
22 B beagle 7 F + - - + - + - - + - - - - + - - 
23 B beagle 8 F + + - + - + - - + - - - - + - - 
24 F beagle 10 F + + - + - + - - - - - + - - + - 
25 F beagle 10 f + + - + - + - - - - - + - - + - 
26 F beagle 10 M + + - + - + - - - - - + - - + - 
27 F beagle 6 M + + - + - + - - - - - + - - + - 
28 F beagle 6 M + + - + - + - - - - - + - - + - 
29 F beagle 12 m + + - + - + - - - - - + - - + - 
30 F beagle 12 m + + + + - + - - - - - + - - + - 
31 F beagle 10 F + + + + - + - - - - - + - - + - 
32 F beagle 10 f + + + + - + - - - - - + - - + - 
33 F beagle 7 M + + + + - + - - - - - + - - + - 
34 F beagle 7 M + + - + - + - - - - - + - - + - 
35 F beagle 6 M + + - + - + - - - - - + - - + - 
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Dog No. 10, marked with asterisk (*), corresponds to the dog No. 10 in the Table 1 (see explanation in Chapter 
4.2). ABG, arterial blood gases; BAL, bronchoalveolar lavage; B, Belgium; B ET-1, BAL fluid endothelin-1; 
B PIIINP, BAL fluid procollagen type III amino terminal propeptide; echo, echocardiography; F, Finland or 
female;  f, neutered female; histo, histological examination of lung tissue; HRCT, high resolution computed 
tomography; M, male; m, neutered male; THX XR, thoracic radiography;  s ET-1, serum endothelin-1; s 
PIIINP serum procollagen type III amino terminal propeptide; v.blood, venous blood; whwt, West Highland 
white terrier. 
4.2     SELECTION OF SAMPLES FOR HISTOPATHOLOGICAL 
STUDY (STUDY IV) 
Post-mortem lung samples obtained from 18 WHWTs with CIPF were included in Study 
IV. Samples from 15 of the 18 WHWTs had been collected at the Department of Veterinary 
Biosciences of the University of Helsinki. Samples from three additional cases were 
provided by the Veterinary Teaching Hospital of the University of Liège. These included 
lung samples from one WHWT from Austria, one from Belgium and one from the 
Netherlands. The signalment, examinations performed prior to euthanasia and the inclusion 
of these WHWTs in other studies of this dissertation are shown in Table 1.  
One of the WHWTs with CIPF participated in Studies I, II and III as a healthy control 
dog. At the dates of those studies, this dog had no signs or findings indicating lung disease. 
The dog was euthanised 31 months later at the age of 16.5 years for reasons other than lung 
disease (incontinence, poor eyesight and weakness of the pelvic limbs). The diagnosis of 
mild CIPF was made on necropsy. 
Three control cases were included. These were post-mortem lung samples which had 
been collected during routine necropsy from three WHWTs at the Department of Veterinary 
Biosciences of the University of Helsinki.  The dogs had been euthanised for reasons other 
than lung disease (intestinal intussusception, joint disease and dementia). All control cases 
underwent a complete necropsy examination. The signalment, the examinations performed 
prior to euthanasia and inclusion in other studies of this dissertation are shown in Table 4. 
Lung samples from four human patients with clinical, radiological and histopathological 
findings consistent with UIP, and four human patients with clinical, radiological and 
histopathological findings consistent with NSIP were included. These were either diagnostic 
biopsy samples or lung transplantation samples, and they were obtained from the 
Department of Pathology, University of Helsinki, Finland. 
4.3   APPROVAL OF STUDY PROTOCOLS 
The protocols of Studies I and III were approved by the Committee of Experimental 
Animals of Western Finland and the protocol of Study II by the Committee of Animal 
Experimentation of the University of Liège.  The owners of the prospectively recruited 
WHWTs with CIPF and healthy WHWTs provided written consent for participation.  
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Ethical permission to obtain informed consent from human patients was received from 
the Helsinki University Hospital Ethical Board. The permission to use tissue samples from 
deceased patients was obtained from the National Supervisory Authority of Welfare and 
Health.   
4.4   CLINICOPATHOLOGICAL EXAMINATIONS 
The owners of the dogs were questioned about clinical signs and a thorough physical 
examination was carried out. In WHWTs with CIPF and healthy WHWTs, standardised 
clinical record forms were used for both purposes. 
4.4.1   BIOCHEMICAL, HAEMATOLOGIC AND FAECAL EXAMINATION 
Blood was drawn either from the cephalic or jugular vein and placed in plain tubes for serum 
biochemistry and ethylenediaminetetraacetic acid tubes for haematological analyses.  
A 3-day faecal sample was collected by owners and examined for parasites using the 
Baermann and flotation methods. 
4.4.2   ARTERIAL BLOOD GAS ANALYSIS 
The samples for arterial blood gas analysis were taken from the femoral or dorsal metatarsal 
artery. The dogs were not sedated for sample collection and were breathing room air.  PaO2, 
partial pressure of arterial carbon dioxide (PaCO2), alveolar-arterial oxygen gradient (P[A-
a]O2), pH, bicarbonate, and acid base excess were analysed immediately with a blood gas 
analyser (ABL800 FLEX, Radiometer) at 37ºC. 
4.4.3   THORACIC RADIOGRAPHY AND ECHOCARDIOGRAPHY 
Right and left lateral and ventrodorsal radiographs were obtained from all dogs with CIPF 
and healthy control WHWTs. From healthy beagles and dogs with CB or EBP, single 
laterolateral and ventrodorsal radiographs were taken.  
Echocardiography was performed by one of the authors of the studies (MMR) (Philips 
iE33, Philips). All dogs underwent complete echocardiographic examination using 
standardised left and right lateral views. 
4.4.4   HIGH RESOLUTION COMPUTED TOMOGRAPHY 
The dogs were pre-medicated with an intramuscular administration of butorphanol 
(Torbugesic, Fort Dodge Animal Health). Anaesthesia was induced with midazolam 
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(Midazolam Halemn, Algol Pharma) and propofol (PropoVet, Abbot Logistics). An HRCT 
study was then performed under isoflurane inhalation anaesthesia (Isoba Vet, Schering-
Plough Ltd).  
The dogs were laying either in dorsal or ventral recumbency and were ventilated before 
the HRCT scan. Data was obtained with a helical dual slice scanner (Somatom Emotion 
Duo, Siemens AG) during the respiratory pause.  Slice thickness was 1.0 mm and table 
movement was 7.5 mm. The images were viewed in Syngo Multi Modality Workplace 
(Siemens AG) by a one of the authors of study I (AKL), who was blinded to the dog’s 
disease status.   
The HRCT findings were categorised according to a classification scheme published 
previously (Johnson et al., 2005). Each radiographic and HRCT finding was scored as 
normal, mild, moderate or severe. In HRCT, a subtle lesion which was only present in one 
lung lobe was assessed as mild. When subtle lesions were present in several lobes or the 
lesion was distinct it was considered as moderate. A widespread and extensive lesion was 
evaluated as severe even if present in one lung lobe only.  Quantitative CT values of the 
nondependent parts of the lung lobes were measured and mean CT values were calculated. 
4.4.5   BRONCHOSCOPY AND BRONCHOALVEOLAR LAVAGE 
Bronchoscopy and BAL were performed with a videoendoscope (Olympus GIF-N180, 
Olympus Europa GmbH; Fujinon EB-4105, Fujinon Europe) using intravenous propofol 
anaesthesia (PropoVet, Abbot Logistics; Diprivan, AstraZeneca). Dogs were preoxygenated 
for 5 minutes before the procedure. All sick and healthy WHWTs were premedicated as for 
HRCT, but in other dogs various anaesthetic protocols were used. Those included 
intramuscular or intravenous administration of medetomidine (Domitor, Orion Pharma), 
dexmedetomidine (Dexdomitor, Orion Pharma), or combinations of acepromazine 
(Combistress, Phenix SA), midazolam (Dormicum, Roche), buprenorphine (Temgesic, 
Schering Plough) and methadone (Mephenon, Federa SC). 
The presence of tracheal collapse, bronchial mucus, bronchial mucosal irregularity, 
bronchiectasis and bronchomalacia were reported. At least two different lung lobes were 
lavaged with sterile, warmed (37oC) saline. The amount of lavage fluid was either 2 mL/kg 
divided into two aliquots (Finnish dogs) or 60 ml divided into three aliquots (Belgian dogs). 
The BALF sample was processed as described previously (Clercx et al., 2000; Rajamäki et 
al., 2001). BALF analysis consisted of total cell count (TCC), differential cell count 
calculations and a quantitative bacterial culture. The limit of infection was set to bacterial 
growth of 103 CFU/mL (Peeters et al., 2008). 
Endoscopic biopsies of bronchial mucosa were obtained from 27 dogs if CB or EBP was 
suspected. Samples were fixed in 10% neutral buffered formalin, processed routinely, and 
sections were stained with hematoxylin and eosin (HE). 
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4.5   ANALYSIS OF FIBROSIS BIOMARKERS (STUDIES II, III) 
4.5.1   ENDOTHELIN-1 ANALYSIS 
Blood samples were collected in dry tubes, centrifuged immediately and the collected serum 
was stored at -20°C until analysis. A BALF sample was immediately centrifuged and the 
supernatant was stored at -80°C within 30 min after BALF sampling until further analysis.  
ET-1 analysis was performed with a human sandwich ELISA kit (Endothelin-1 Assay 
kit, IBL). The method has been validated previously for use in canine serum (Schellenberg 
et al., 2008). This kit had a sensitivity of 0.23 ρg/mL. Before measurement, a pre-step of 
extraction, using Sep-Pak C-18 column (Waters Corporation, Milford) was required to work 
on the serum. This step permitted a two-fold concentration of the sample in ET-1. It was 
also performed on BALF samples to increase the likelihood of ET-1 concentration being 
above the detection limit. 
4.5.2   PIIINP ANALYSIS 
Serum and BALF PIIINP concentrations were measured using a commercially available 
radioimmunoassay (UniQPIIINP radioimmunoassay, Orion Diagnostics) which was based on 
purified human PIIINP. The method has previously been validated for use on canine serum 
and BALF (Schuller et al., 2006). All measurements were taken in duplicate. The detection 
limit of the assay was 0.03 μg/L. Values below this were given an artificial value of 0.02 
μg/L. 
4.6   HISTOPATHOLOGICAL ANALYSIS (STUDY IV) 
4.6.1   SAMPLING LOCATION AND PREPARATION OF SAMPLES 
The samples chosen for Study IV were collected from the cranial and caudal lung lobes of 
nine WHWTs with CIPF and from the caudal lobes only in three other cases. For the 
remaining six dogs with CIPF and for the three control dogs, the location of samples 
collected was not specified. The samples had been fixed in 10% neutral buffered formalin, 
embedded in paraffin wax and sectioned (4 μm) for routine HE staining.  
Five different lung sections were reviewed from each of the 14 WHWTs with CIPF, and 
from the controls.  Only one section of lung was available for review from four dogs with 
CIPF.  
Based on the histopathological findings in the HE stained sections, one slide with lesions 
most morphologically compatible with human UIP was selected from each of the 18 cases 
and stained with Masson’s trichrome stain for collagen. Further serial sections of the slide 
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were subjected to immunohistochemistry (IHC)  with antibodies specific for α-smooth 
muscle actin (SMA) (Clon 1A4 Dako) and desmin (Clone D33 Dako) in order to visualise 
myofibroblasts and smooth muscle hyperplasia, and cytokeratin (CK) (AE1/AE3 
DakoCytomation) and human high molecular weight cytokeratin (HMW-CK) (34ßE12, 
DakoCytomation) to investigate the epithelial changes. 
The human samples were included in the staining and immunohistochemical protocols 
described above. 
4.6.2   HISTOPATHOLOGICAL EXAMINATION 
All canine samples were examined for the severity and distribution pattern of interstitial 
fibrosis, the presence of honeycombing, the temporal appearance of the fibrosis, smooth 
muscle hyperplasia, PCII hyperplasia and atypia, interstitial inflammation, other 
inflammatory changes, such as bronchitis and pleuritis, and alveolar luminal changes, 
including histiocytosis, proteinosis and diffuse alveolar damage (DAD).  
The severity of the interstitial fibrosis was graded subjectively as mild, if the 
approximated thickness of alveolar septae did not exceed that of controls, but the alveolar 
capillaries in the septae were obscured or partially replaced by interstitial collagen. The 
fibrosis was graded as moderate if the alveolar septae were up to twice the thickness of those 
in mild lesions and was graded as severe if exceeding this.  
Honeycombing was noted as cystic, fibrotic airspaces, lined by low columnar epithelium 
expressing HMW-CK, which in the normal lung is expressed only by basal bronchiolar cells 
renewing bronchial and bronchiolar epithelium.  
Dense collagen deposition, staining deep blue with Masson’s trichrome stain, with low 
cellularity showing slender spindle-shaped nuclei consistent with fibrocytes, was interpreted 
as mature fibrosis. The fibrosis was interpreted as immature if the matrix was light blue or 
myxoid with Masson’s trichrome stain, and the cellularity was increased, consisting of 
ovoid vesicular nuclei interpreted as fibroblasts.  
Myofibroblasts were identified among the fibroblasts based on positive SMA labelling 
and negative desmin labelling in serial sections.  
Cuboidal CK positive cells lining the alveolar luminal surface were interpreted as PCII 
hyperplasia and spindle shaped, broad based, occasionally multinucleated, CK positive cells 
in the same location were noted as PCII atypia.  
In the nine dogs where all lobes were sampled, the presence or absence of honeycombing 
and severe fibrosis was noted in each lobe, in order to describe the lobar distribution of the 
most severe lesions. 
4.6.3   COMPARISON WITH HUMAN DISEASE 
The histopathological findings in WHWTs with CIPF were compared with the key features 
of human UIP and NSIP (American Thoracic Society, European Respiratory Society, 2002; 
Katzenstein et al., 2008; Raghu et al., 2011). Lung samples from human patients with UIP 
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or NSIP were used to provide the depicted comparison of the histopathological findings in 
WHWTs with CIPF and human disease. 
4.7   STATISTICAL ANALYSIS 
Analyses were performed using commercial statistical programmes (PASW Statistics 18.0 
for Windows, SPSS Inc.; Statistical Analysis Systems Institute, Cary). Normality was 
evaluated via the Shapiro-Wilk test. Data was presented as mean and standard deviation 
(SD) or median and interquartile (IQ) range. For pairwise comparisons, either unpaired 
Student’s t-test (data with Gaussian distribution) or Mann Whitney U-tests (non-normally 
distributed data) were used. Spearman Rank Correlation was used for all correlations. All 
comparisons were performed 2-tailed.  
In Study II, the influences of age and disease group (CIPF, CB, EBP, healthy beagles, 
healthy WHWTs) on ET-1 concentrations were analysed by 2-way ANOVA in all groups 
of dogs together. If the effect of age, group, or both was statistically significant, it was 
studied further by Mann-Whitney U-test. In Study III, the disease groups were compared 
with either ANOVA or Kruskal-Wallis one-way ANOVA on ranks. In the latter case, the 
Mann-Whitney U-test was used for pairwise comparisons.  
Receiving operating characteristic (ROC) curves were created to analyse the ability of 
serum ET-1 concentration and BALF PIIINP concentration to differentiate CIPF from CB, 
and serum ET-1 concentration to differentiate CIPF from CB and EBP.  
The differences were considered statistically significant if P < 0.05.
 5   RESULTS 
5.1   CLINICOPATHOLOGICAL FINDINGS IN DOGS WITH CIPF 
COMPARED WITH HEALTHY CONTROL WHWTS 
The results of 14 WHWTs and one Scottish terrier with CIPF are presented and compared 
with 14 healthy control WHWTs. 
5.1.1   SIGNALMENT, CLINICAL SIGNS AND PHYSICAL EXAMINATION 
A summary of the signalment of the dogs with CIPF and healthy control WHWTs is given 
in Table 5. Details of the individual dogs are shown in Table 1 (CIPF) and Table 4 (healthy 
WHWTs). 
At presentation, ten dogs with CIPF were receiving medications (e.g. prednisolone, 
theophylline, furosemide, benazepril, pimobendan, trilostane, or thyroxin). One CIPF dog 
had hyperadrenocorticism, and another had hypothyroidism both of which were controlled 
with medication. One had a urinary tract infection, and another had pyelonephritis. One 
control dog was receiving prednisolone and cyclosporin for dermatologic problems.  
The most common clinical sign was the combination of cough and exercise intolerance 
described in 8/15 CIPF dogs. Exercise intolerance as the sole problem was reported in 3/15 
and cough in 2/15 dogs.  One dog had experienced only gagging and another panting. The 
mean duration of signs was 14 months (range 2-29 months).  
The general condition of 13/15 dogs was good, and the dogs were bright and alert.  The 
remaining two dogs were both dyspnoeic and tachypnoeic, and one of those was also 
cyanotic. Abdominal breathing was reported in 10/15 dogs with CIPF. Diffuse inspiratory 
pulmonary crackles described as “Velcro crackles” were detected bilaterally in 12/15 dogs. 
Two dogs were normal on auscultation and one had ronchi. In three dogs the Velcro crackles 
were also audible without a stethoscope. None of the dogs had wheezes on auscultation.    
The control dogs did not have any signs or findings indicating lung disease. 
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Table 5 Summary of the signalment. 
 CIPF 
 
n = 15 
CB 
 
n = 22 
EBP 
 
n = 15 
healthy 
WHWT 
n = 14 
healthy 
beagle 
n = 21 
Sex   
♂/ neutered ♂ 
 
8 / 0 
 
9  / 1 
 
6 / 2 
 
2 / 3 
 
9 / 2 
♀/ neutered ♀ 4 / 3 6 / 6 4 / 3 5 / 4 8 / 2 
Age (years) 
mean ? SD (range) 
12 ? 2  
(8-15) 
9 ? 3  
(1-15) 
6 ? 3  
(1-12) 
9 ? 3  
(3-14) 
8 ? 2  
(3-12) 
Weight (kg) 
mean ? SD (range) 
10 ? 2  
(8-13) 
22 ? 14  
(4-49) 
21 ? 11  
(8-44) 
9 ? 1  
(8-12) 
15 ? 2  
(9-19) 
CB, chronic bronchitis; CIPF, canine idiopathic pulmonary fibrosis; EBP, eosinophilic 
bronchopneumopathy; WHWT, West Highland white terrier. 
5.1.2   BIOCHEMICAL, HAEMATOLOGICAL AND FAECAL EXAMINATIONS 
 
Biochemical and haematological samples were obtained from 13/15 CIPF dogs and 14/14 
controls. The following dogs were then excluded from analyses: four CIPF dogs and one 
control dog receiving prednisolone, one CIPF dog with hyperadrenocorticism and one CIPF 
dog with pyelonephritis. The analyses were therefore performed on 7 dogs with CIPF and 
13 control dogs.  
Only the serum concentration of alkaline phosphatase (ALP) and platelet count were not 
within reference ranges. The ALP concentration was increased in 6 of the remaining 7 dogs 
with CIPF and in 5 of the remaining 13 control WHWTs. Thrombocytosis was seen in 6/7 
dogs with CIPF and in 12/13 controls. The mean ALP concentration was 454 U/L (range 
190-827 U/L) in CIPF and 282 U/L (range 54-654 U/L) in controls (reference range 33-215 
U/L). The mean thrombocyte count was 534,000/μL (range 370,000-720,000/μL) in CIPF 
and 556,000/μL (range 356,000-880,000/μL) in controls (reference range 102,000-
395,000/μL). The mean haematocrit was 52% (range 33-61%) in CIPF and 51% (range 38-
59%) in controls (reference range, 38-57%). The ALP concentration, thrombocyte count, 
and haematocrit did not differ between the dogs with CIPF and healthy WHWTs. All faecal 
samples were negative for parasites.  
5.1.3   ARTERIAL BLOOD GAS ANALYSIS 
Arterial blood gases were obtained from 11/15 dogs with CIPF and 12/14 control dogs. The 
results are given in Table 6. 
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Table 6 Arterial blood gas values in WHWTs with CIPF (n=11) and healthy control 
                  WHWTs (n=12), given as mean ± SD and range. 
 Dogs with CIPF Control WHWTs 
PaO2 (mmHg)* 60.8 ? 15.4 (33.5-87.4) 99.1 ? 7.8 (89.6-113.0) 
P(A-a)O2 (mmHg)* 55.3 ? 16.5 (28.0-84.7) 17.5 ? 4.9 (10.7-26.8) 
PaCO2 (mmHg) 29.2 ? 3.9 (25.0-35.7) 28.7 ? 3.8 (20.5-34.6) 
pH 7.454 ? 0.036 (7.407-7.529) 7.467 ? 0.053 (7.407-7.569) 
HCO3- (mmol/L) 21.0 ? 2.5 (17.4-25.9) 20.4 ? 1.9 (17.6-23.0) 
ABE (mmol/L) -1.7 ? 2.5 (-6.0-3.1) -1.5 ? 2.1 (-5.0-1.3) 
ABE, acid base excess; CIPF, canine idiopathic pulmonary fibrosis; HCO3-, bicarbonate; P(A-a)O2, alveolar-
arterial oxygen gradient; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of 
arterial oxygen; WHWT, West Highland white terrier. 
* Statistically significant difference, P < 0.001 
5.1.4   THORACIC RADIOGRAPHY AND ECHOCARDIOGRAPHY 
Thoracic radiographs were taken from 13/15 dogs with CIPF and all control dogs. The most 
common radiographic finding was bronchointerstitial pattern seen in 8/13 CIPF dogs 
(moderate in 3/13, severe in 5/13) (Fig. 4).  Three of thirteen CIPF dogs had patchy alveolar 
opacities with indistinct margins in one or two lung lobes. The most common pattern in 
controls was mild bronchial or bronchointerstitial pattern, which was considered normal. 
Mean vertebral heart score was 10.2 in both groups (range 9.5-11.1 in CIPF and 9.3-10.8 in 
controls).  
Echocardiography was performed on 10/13 dogs with CIPF and all control dogs. It 
disclosed right-sided cardiac enlargement in 7/10 CIPF dogs. Tricuspid valve dysplasia and 
pulmonary stenosis were eliminated in all dogs. Left-sided heart disease was also not 
detected. 
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Figure 4 Right lateral (A) and dorsoventral (B) radiographs obtained from a 12 year old male 
West Highland white terrier with canine idiopathic pulmonary fibrosis (PaO2 82 
mmHg). The radiographs show a moderate (B) to severe (A) generalised 
bronchointerstitial lung pattern and a large cardiac shadow.  
5.1.5   HIGH RESOLUTION COMPUTED TOMOGRAPHY 
HRCT was performed on 7/15 dogs with CIPF and 11/14 control dogs. On HRCT, several 
lesions were detected in each dog with CIPF. In the majority of the dogs, the predilection 
site for the lesions was the dorsocaudal lung lobes.  GGO was seen in all dogs (severe in 
4/7, moderate in 3/7). Parenchymal bands were visible in 5/7 dogs (mild in 1/7, moderate in 
3/7, severe in 1/7), subpleural lines in 2/7, moderate subpleural interstitial thickening in 1/7, 
moderate peribronchovascular interstitial thickening in 3/7, consolidation in 5/7, traction 
bronchiectasis in 5/7, and honeycombing in 2/7 dogs. Traction bronchiectasis and 
honeycombing occurred simultaneously in 2/7 dogs.   
In 4/11 controls, no changes were recorded. Eight of 11 controls had only one or two 
focal lesions in the dependent part of the lung. Consolidation, traction bronchiectasis, 
subpleural lines, subpleural interstitial thickening, and honeycombing were not seen in any 
of the controls (Fig. 5).  
The CT values (given as Hounsfield units, HU) were significantly higher in CIPF (mean 
-731 ± SD 51 HU, range -695 to -786 HU) compared with the controls (-821 ± 36 HU, -761 
to -862 HU, respectively; P < 0.001). No correlation with PaO2 was detected.    
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Figure 5 (A) Normal lung. High resolution computed tomography (HRCT) image of the lung of 
a healthy, 8 year old West Highland white terrier (WHWT). The red circle represents 
one of the investigated regions of interest (ROI). CT-value was here -848 Hounsfield 
units (HU). (B) Canine idiopathic pulmonary fibrosis (CIPF). The HRCT image 
demonstrates areas of ground glass opacity (GGO) and traction bronchiectasis (TB). 
CT-value of the ROI shown here was -707 HU. The scan was obtained from a 10 year 
old WHWT with severe hypoxemia (partial pressure of arterial oxygen [PaO2] 50.6 
mmHg). Both dogs (A, B) were scanned on dorsal recumbency. (C) CIPF. The HRCT 
image shows a parenchymal band (PB) and areas of GGO. The scan was obtained 
from an 11 year old WHWT (PaO2 61.3 mmHg). (D) CIPF. The HRCT image 
illustrates a subpleural line (SL) and an area of honeycombing (HC) and TB. This 
dog was a 14 year old WHWT that was not hypoxemic (PaO2 87.4 mmHg). These 
dogs (C, D) were scanned on ventral recumbency. 
5.1.6   BRONCHOSCOPY AND BRONCHOALVEOLAR LAVAGE 
Bronchoscopy and BAL were performed on 13/15 dogs with CIPF and 11/14 control dogs. 
Bronchoscopic results were available only from 9 dogs with CIPF and all control dogs. The 
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findings in dogs with CIPF were bronchial mucosal irregularity (9/9), tracheal collapse (6/9) 
(grade I in 3/9, grade III in 3/9), mild to moderate amount of bronchial mucus (3/9), mild 
bronchiectasis (3/9 dogs), and bronchomalacia (5/9) (Fig. 6). Three of 11 controls had grade 
I tracheal collapse. Mild mucosal irregularity was seen in 7/11 controls. 
BALF results were available from 12 dogs with CIPF and 12/14 control dogs. Analyses 
of BALF are shown in Table 7. BALF TCC, macrophages, neutrophils, mast cells, and mast 
cell percentage correlated negatively with PaO2 (ρ = -0.649, P = 0.002; ρ = -0.593, P = 
0.007; ρ = -0.596, P = 0.006; ρ = -0.539, P = 0.017; ρ = -0.492, P = 0.032, respectively).  
Lymphocyte percentage had a positive correlation with PaO2 (ρ = 0,642, P = 0.003). No 
bacterial growth was detected. 
   
   
Figure 6 (A) Bronchoscopic view of a normal bronchus. The image was obtained from a 4 year 
old healthy West Highland white terrier (WHWT). (B) Bronchial mucosal irregularity 
of moderate severity detected in a 12 year old WHWT with canine idiopathic 
pulmonary fibrosis (CIPF). (C) Grade I tracheal collapse viewed at the level of 
carina in a 12 year old WHWT with CIPF. (D) Severe bronchial mucosal irregularity 
with mild bronchiectasis. The image was taken from a 13 year old WHWT with CIPF. 
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Table 7 Cytological findings in BALF of WHWTs with CIPF (n = 12) and healthy control    
                   WHWTs (n = 11), given as median, IQ, and range. 
 CIPF dogs Control WHWTs 
Recovered volume (%) 55, IQ 49-69 (35-65) 56, IQ 49-69 (40-76) 
Total cell count (cells/?L)** 783, IQ 455-1075 (280-3115) 350, IQ 280-380 (265-420) 
Macrophages (%) 84, IQ 66-87 (64-93) 78, IQ 76-82 (69-89) 
      cells/?L** 669, IQ 324-957 (178-2500) 269, IQ 225-289 (194-375) 
Lymphocytes (%)* 6.4, IQ 4.8-11 (1.7-30) 16, IQ 14-19 (9.2-21) 
      cells/?L 51, IQ 29-79 (14-335) 56, IQ 42-63 (39-79) 
Neutrophils (%) 4.4, IQ 3.5-21 (3.0-30) 4.5, IQ 3.1-4.7 (0.9-6.2) 
      cells/?L** 41, IQ 25-120 (10-753) 14, IQ 11-17 (2.8-18) 
Eosinophils (%)* 0.0, IQ 0.0-0.0 (0.0-2.0) 0.4, IQ 0.0-0.6 (0.0-2.0) 
      cells/?L 0.0, IQ 0.0-1.8 (0.0-14) 1.5, IQ 0.0-1.8 (0.0-5.6) 
Mast cells (%)* 0.5, IQ 0.4-0.9 (0.0-2.5) 0.3, IQ 0.0-0.4 (0.0-0.9) 
      cells/?L** 3.9, IQ 1.4-11 (0.0-64) 1.1, IQ 0.0-1.6 (0.0-3.2) 
Epithelial cells (%) 0.0, IQ 0.0-1.2 (0.0-9.7) 0.2, IQ 0.0-0.4 (0.0-1.8) 
      cells/?L 0.0, IQ 0.0-6.3 (0.0-78) 0.9, IQ 0.0-1.4 (0.0-6.3) 
Plasma cells (%) 0.0, IQ 0.0-0.0 (0.0-0.6) 0.0, IQ 0.0-0.0 (0.0-0.6) 
      cells/?L 0.0, IQ 0.0-0.0 (0.0-3.3) 0.0, IQ 0.0-0.0 (0.0-2.1) 
BALF, bronchoalveolar lavage fluid; CIPF, canine idiopathic pulmonary fibrosis; IQ, interquartile range; 
WHWT, West Highland white terrier. 
*    Statistically significant difference, P < 0.05  
**  Statistically significant difference, P < 0.01 
5.2   CLINICOPATHOLOGICAL FINDINGS IN OTHER DOGS 
5.2.1   SIGNALMENT 
A summary of the signalment of the dogs is given in Table 5. Details of the individual dogs 
are shown in Table 2 (CB), Table 3 (EBP) and Table 4 (healthy beagles). 
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5.2.2   DOGS WITH CHRONIC BRONCHITIS 
All 22 dogs with CB suffered from coughing, the mean duration of which was 11 months 
(range 2-60 months). Two dogs also had intermittent dyspnoea. All dogs had changes in 
thoracic radiographs, the most frequent being moderate to severe bronchointerstitial opacity. 
Alterations were evident in all dogs on bronchoscopy, including an increased amount of 
mucus (14/22), hyperaemia (11/22), mucosal irregularity (10/22), bronchomalacia (6/22), 
mucosal thickening (3/22), tracheal collapse (3/22) and focal bronchiectasis (1/22). There 
was no significant bacterial growth from BALF. The median value for BALF TCC was 500 
cells/μL (IQ 403-672 cells/μL, range 93-12000 cells/μL) and the median percentage of 
neutrophils was 33% (IQ 3-47%, range 1-90%). In the histopathology of the bronchial 
mucosa, no eosinophilic infiltration was observed. No parasites were detected on faecal 
examination. 
5.2.3   DOGS WITH EOSINOPHILIC BRONCHOPNEUMOPATHY 
Dogs with EBP all had coughing as their main clinical sign. Four dogs were also exercise 
intolerant and three had dyspnoea. The mean duration of clinical signs was 11 months (range 
1 - 26 months).  Blood eosinophilia (eosinophil count > 750 cells/μL was evident in 5/15 
dogs. On thoracic radiography, bronchial opacity was detected in all but one dog. This dog 
had nodular opacities as the sole finding. Interstitial opacities were visible in 8/15 dogs. One 
dog also had focal alveolar infiltrates.  
Bronchoscopic changes were present in all dogs including an increased amount of mucus 
(12/15), mucosal irregularity (8/15), congestion (4/15), mucosal thickening (3/15) and 
bronchospasm (1/15). The median TCC in BALF was 1580 cells/μL (IQ 925- 4175 cells/μL, 
range 400-12900 cells/μL) and the median percentage of eosinophils was 65% (IQ 30-73%, 
range 20-84%). In one dog the eosinophilic percentage was relatively low, 8%, but 
infiltration of eosinophils was detected in bronchial biopsy.  There was no significant 
bacterial growth in BALF and no parasites were detected in faecal examination. 
5.2.4   HEALTHY BEAGLES 
The healthy beagles had no clinical signs, and no abnormalities indicating disease were 
detected in any of the ancillary examinations. 
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5.3   ENDOTHELIN-1 ANALYSIS (STUDY II) 
5.3.1   SERUM ENDOTHELIN-1 CONCENTRATION 
Serum ET-1 concentration from 12 dogs with CIPF was analysed, 13 healthy control 
WHWTs, 9 healthy control beagles, 10 dogs with CB and 6 dogs with EBP. The results and 
the comparison of serum ET-1 concentration between dogs with CIPF and dogs with CB, 
EBP, healthy beagles and healthy WHWTs are shown in Fig. 7. There was no difference 
between healthy WHWTs and beagles (P = 0.063).  Serum ET-1 concentration was 
significantly lower in EBP dogs than in healthy WHWTs (P = 0.001) and healthy beagles 
(P = 0.011). 
In dogs with CIPF, no correlation was found between serum ET-1 concentration and the 
duration of clinical signs, PaO2, P(A-a)O2, or BALF TCC. 
The results of ROC curve analysis of serum ET-1 concentration for distinguishing CIPF 
from CB is illustrated in Fig. 8. 
 
 
 
Figure 7 Serum endothelin-1 (ET-1) concentration in dogs with canine idiopathic pulmonary 
fibrosis (CIPF), chronic bronchitis (CB), eosinophilic bronchopneumopathy (EBP), 
healthy beagles and healthy West Highland white terriers (WHWTs). P values were 
as compared to CIPF dogs. The line indicates the median value and the boxes the 
interquartile range (IQ). The whiskers extend to 1.5 IQ. Values more than that are 
labelled as outliners and marked as dots.   
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Figure 8 Receiver operating characteristic (ROC) curve of serum endothelin-1 (ET-1) 
concentration for differentiating canine idiopathic pulmonary fibrosis from chronic 
bronchitis. The optimal cut-off value of 1.8 ρg/mL, indicated in the figure with an 
asterisk (*), yielded a sensitivity of 100% and a specificity of 85%. The area under 
the ROC curve was 0.86.  
5.3.2   BRONCHOALVEOLAR LAVAGE FLUID ENDOTHELIN-1 
CONCENTRATION 
BALF ET-1 concentration was measured from 6 dogs with CIPF, 5 healthy WHWTs and 5 
dogs with CB. In all CIPF dogs, the ET-1 concentration was measurable in BALF whereas 
in the dogs with CB and in healthy WHWTs, the BALF ET-1 concentration was below the 
detection limit of the assay (Fig. 9). 
In dogs with CIPF, no correlation was found between BALF and serum ET-1 
concentration (P = 0.71). 
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Figure 9 Dot plot of endothelin-1 (ET-1) concentration in bronchoalveolar lavage fluid 
(BALF) of dogs with canine idiopathic pulmonary fibrosis (CIPF), chronic bronchitis 
(CB) and healthy West Highland white terriers (WHWT). Scattered line represents 
the detection limit of the assay.  
5.4   PIIINP ANALYSIS (STUDY III) 
5.4.1   SERUM PIIINP CONCENTRATION 
Serum PIIINP concentration was measured in 13 dogs with CIPF, nine dogs with CB, seven 
dogs with EBP and 13 healthy controls (all WHWTs). There was no statistically significant 
difference in serum PIIINP concentration between the groups (Fig. 10). 
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Figure 10 Serum procollagen type III amino terminal propeptide (PIIINP) concentration in 
dogs with canine idiopathic pulmonary fibrosis (CIPF), chronic bronchitis (CB), 
eosinophilic bronchopneumopathy (EBP) and in healthy dogs (WHWTs and beagles). 
There was no significant difference between the groups. The line indicates the median 
value, the boxes the interquartile range (IQ), the whiskers extend to 1.5 times IQ and 
values more than that are labelled as outliers and represented by dots.  
5.4.2   BRONCHOALVEOLAR LAVAGE FLUID PIIINP CONCENTRATION 
BALF PIIINP concentration was analysed from 13 dogs with CIPF, 19 dogs with CB, 13 
dogs with EBP and 22 healthy control dogs (10 WHWTs and 12 beagles). The results and 
a comparison of BALF PIIINP concentration between CIPF and dogs with CB, EBP and 
healthy dogs are shown in Fig. 11.  
BALF PIIINP concentration was significantly higher in dogs with EBP than in dogs with 
CB (P = 0.003) or healthy dogs (P = 0.022). No statistically significant differences were 
found regarding BALF PIIINP concentration between dogs with CIPF and dogs with EBP 
(P = 0.812), between dogs with CB and healthy controls (P = 0.148) or between healthy 
WHWTs and healthy beagles (P = 0.473).  
No correlation was detected between BALF PIIINP and serum PIIINP concentration. In 
CIPF dogs, BALF PIIINP concentration was not correlated with PaO2, P(A-a)O2 or duration 
of clinical signs.  
The results of ROC curve analysis of BALF PIIINP concentration for distinguishing 
CIPF from CB is illustrated in Fig. 12. 
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Figure 11 Bronchoalveolar lavage fluid (BALF) procollagen type III amino terminal propeptide 
(PIIINP) concentration in dogs with canine idiopathic pulmonary fibrosis (CIPF), 
chronic bronchitis (CB), eosinophilic bronchopneumopathy (EBP) and healthy dogs. 
P values were as compared to CIPF dogs. The line indicates the median value, the 
boxes the interquartile range (IQ), the whiskers extend to 1.5 times IQ and values 
more than that are labelled as outliners and marked as dots.  
 
Figure 12 Receiver operating characteristic (ROC) curve of bronchoalveolar lavage fluid 
(BALF) procollagen type III amino terminal propeptide (PIIINP) concentration for 
differentiating canine idiopathic pulmonary fibrosis from chronic bronchitis. The 
optimal cut-off value 0.1 μg/L, indicated in the figure with an asterisk (*), yielded a 
sensitivity of 69% and a specificity of 95%. The area under the ROC curve was 0.81. 
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  5.5   HISTOPATHOLOGY (IV) 
The age of the WHWTs with CIPF from which the lung samples were obtained varied 
between 8 and 16 years (median 12 years). The control WHWTs were 2, 6 and 12 years of 
age. 
5.5.1   INTERSTITIAL FIBROSIS 
A pattern of diffuse and mature fibrosis was present in the alveolar walls of all the 18 
WHWTs studied. This diffuse fibrosis was graded either as mild (11/18 dogs) or moderate 
(7/18 dogs). It was equally present in different lung lobes. Perivascular concentric 
accumulation of collagen was visible around pre- and post-capillary small vessels in all 18 
WHWTs. None of the control dogs showed these lesions (Fig. 13A and B).   
In addition to the mature diffuse fibrosis, the majority of the WHWTs (11/18 dogs) also 
had multifocal areas of fibrosis accentuation. In these areas the fibrosis was more severe 
and more cellular. The areas of accentuated fibrosis were located around the bronchioli or 
under the pleura (Fig. 13C). Honeycomb change, a cystic airspace lined by metaplastic 
bronchiolar epithelium, was detected in 7 of 11 WHWTs in the areas of fibrosis accentuation 
(Fig. 13D). Interstitial smooth muscle hyperplasia was present in 9 of these 11 WHWTs. 
Myofibroblasts were diffusively present in the fibrotic alveolar interstitium in the areas of 
accentuated fibrosis (Fig. 14A, B and C). Fibroblast foci, prominent interstitial foci of 
fibroblasts and myofibroblasts beneath the alveolar epithelium, were not found.  
5.5.2   ALVEOLAR EPITHELIAL AND LUMINAL CHANGES 
PCII atypia was present in 17 of 18 WHWTs with CIPF. In twelve of these dogs PCII 
hyperplasia was also detected (Fig. 15A). The presence of atypical PCII cells was limited 
to the multifocal areas of more severe fibrosis in 11 WHWTs. In the remaining 6 WHWTs 
with PCII atypia but no areas of severe fibrosis, atypical PCII cells were scattered in the 
alveolar septa throughout the lung samples. One dog with diffuse mature fibrosis and 
multifocal fibrosis accentuation areas had no epithelial changes.  
Bronchiolar metaplasia of the alveolar epithelium, indicated by a strong expression of 
HMW-CK in epithelial cells covering the alveolar walls, was present in 11 of 18 WHWTs 
with CIPF in peribronchiolar fibrotic areas (Fig. 15B). Six of these WHWTs also had 
epithelial pseudostratification and squamous metaplasia.  
A mild to moderate amount of foamy macrophages was detected in alveolar lumens in 
13 of 18 WHWTs (Fig. 15C). This accumulation of macrophages was restricted to areas of 
disease accentuation. Intra-alveolar accumulation of proteinaceous material, manifested as 
a dense, eosinophilic and homogenous substance, was detected in 14 of 18 WHWTs with 
CIPF. This change was not related to areas of fibrosis accentuation, instead it was 
multifocally randomly distributed throughout the lung.  
5   Results 
 
 
 
 
57 
DAD presented as hyaline membranes lining the alveolar luminal walls, coinciding with 
hyperplastic PCII cells, scattered alveolar septal neutrophils, and alveolar septal congestion, 
was detected in 5 of 18 WHWTs with CIPF (Fig. 15D). DAD was limited to the areas of 
fibrosis accentuation. Consecutive luminal organising fibrosis was seen in these five 
WHWTs and also in two WHWTs with CIPF without DAD change.  
Alveolar epithelial changes were not present in any of the control dogs. The two and six 
year old control dogs had mild alveolar oedema. 
  
       
   
     
Figure 13 Histopathological features of canine idiopathic pulmonary fibrosis in West Highland 
white terriers (WHWTs). (A) Lung histology of a healthy control WHWT. HE, Bar 
200 μm. Inset: Vessel of a healthy control WHWT. Masson’s trichrome. (B) Mild 
diffuse mature interstitial fibrosis. HE. Bar, 200 μm. Inset: Perivascular concentric 
fibrosis. Masson’s trichrome (C) Focus of accentuated disease with severe interstitial 
fibrosis and pneumocyte type II hyperplasia. HE. Bar, 200 μm. (D) Subpleural area 
of honeycombing and severe interstitial fibrosis. HE. Bar, 1 mm. Inset: Cystic fibrotic 
airspace within areas of honeycombing. Masson’s trichrome. The images are taken 
from the publication IV.  
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Figure 14 Histopathological and immunohistochemical characteristics of the progressing 
fibrosis in canine idiopathic pulmonary fibrosis of West Highland white terriers. (A) 
Multifocal to coalescing areas of interstitial less mature fibrosis (asterisk). Masson’s 
trichrome. Bar, 200 μm. (B) Serial section of (A), showing SMA positivity in the area 
of more cellular fibrosis (asterisk). IHC SMA. Bar, 200 μm. (C) Serial section of (A) 
and (B) negative for desmin in areas of SMA positivity (asterisk), consistent with 
presence of myofibroblasts in areas of progressing fibrosis. IHC desmin. Bar, 200 
μm. (D) Immature fibrosis organising along a central core of collagen-rich 
interstitial fibrosis (arrow) within the alveolar wall. Masson’s trichrome. Bar, 200 
μm. The images are taken from the publication IV. 
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Figure 15 Alveolar epithelial and luminal changes of canine idiopathic pulmonary fibrosis in 
West Highland white terriers. (A) Pneumocyte type II (PCII) atypia. Broad-based 
(short arrow) and occasional multinucleated (long arrow) PCII cells lining the 
alveolar septa. IHC CK. Bar, 100 μm. (B) Metaplasia of bronchiolar epithelium. 
HMW-CK positive hyperplastic (short arrow) and occasionally metaplastic (long 
arrow) epithelial cells on peribronchiolar alveolar septa. Basal bronchiolar cells 
expressing HMW-CK in a normal bronchiole are shown by an asterisk.  IHC HMW-
CK, Bar 200 μm. (C) Interstitial smooth muscle metaplasia, desquamating alveolar 
macrophages and PCII hyperplasia within the severe fibrotic areas. HE. Bar, 20 μm. 
(D) Acute alveolar damage with hyaline membrane formation. HE. Bar, 20 μm. The 
images C and D are taken from the publication IV. 
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5.5.3   INFLAMMATION  
In addition to interstitial fibrosis, all WHWTs with CIPF showed interstitial 
lymphoplasmacytic inflammation with few macrophages. The inflammation was considered 
mild in 13 of 18 WHWTs and moderate in 5 of 18 WHWTs. Eight WHWTs with CIPF had 
concurrent mild to moderate lymphoplasmacytic bronchitis and three WHWTs had 
multifocal, mild, chronic fibrosing pleuritis.  
The oldest control WHWT had multifocal mild peribronchiolar lymphoplasmacytic 
inflammation. The two other control WHWTs had no inflammatory changes in their lung. 
5.5.4   OTHER FINDINGS  
Interstitial anthracosis was seen in all WHWTs with CIPF and in all control WHWTs. It 
was described as mild to moderate, multifocal, peribronchiolar and perivascular in 16 
WHWTs with CIPF and in control WHWTs, and severe in 2 WHWTs with CIPF.  
Thrombosis of pulmonary vessels with partial organisation of thrombi was detected in 
two WHWTs with CIPF. One of those dogs had moderate and one had severe pulmonary 
changes. No vascular changes were detected in the control dogs. 
5.5.5   DISTRIBUTION OF THE MOST SEVERE LESIONS 
Histological samples from all lung lobes were obtained from 9 of the 18 WHWTs with 
CIPF. Table 8 presents a comparison of the severity of the histopathological lesions between 
different lung lobes in these nine dogs. Severe multifocally accentuated lesions, indicated 
by severe interstitial fibrosis and/or profound alveolar epithelial and luminal changes and 
inflammation, were present in the caudal lobes in three dogs and in the cranial lobes in one 
dog with mild diffuse fibrosis. In all five dogs with moderate diffuse fibrosis, both cranial 
and caudal lung lobes showed multifocally accentuated lesions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5   Results 
 
 
 
 
61 
Table 8  Comparison of the severity of the histopathological lesions between different lung   
                   lobes in nine WHWTs with CIPF. 
Dog 
No. 
Age 
years 
Diffuse 
fibrosis 
Multifocally 
accentuated 
fibrosis 
Cranial lobes Caudal lobes Middle 
lobe 
Accessory 
lobe 
left right left right 
1 16 mild not present more severe 
less 
severe 
less 
severe 
less 
severe 
less  
severe 
less  
severe 
2 13 mild moderate less severe 
less 
severe 
more 
severe 
more 
severe 
less  
severe 
less  
severe 
3 15 mild moderate less severe 
less 
severe 
more 
severe 
more 
severe 
more 
severe 
more  
severe 
4 14 mild severe less severe 
less 
severe 
more 
severe 
more 
severe NA NA 
5 12 moderate not present equal equal equal equal NA NA 
6 8 moderate not present equal equal equal equal equal equal 
7 13 moderate severe equal equal equal equal equal equal 
8 12 moderate severe equal equal equal equal NA NA 
9 12 moderate severe equal equal equal equal NA NA 
CIPF, canine idiopathic pulmonary fibrosis; NA, not applicable; WHWT, West Highland white terrier. 
5.5.6   COMPARISON WITH HUMAN USUAL INTERSTITIAL PNEUMONIA 
AND NONSPECIFIC INTERSTITIAL PNEUMONIA 
Table 9 summarises the histopathological classification criteria of human UIP and NSIP 
(American Thoracic Society, European Respiratory Society, 2002; Katzenstein et al., 2008; 
Raghu et al., 2011), and their presence or absence in the lungs of the WHWTs with CIPF.  
In 7 of the 18 WHWTs with CIPF, the histopathological findings resembled fibrosing 
NSIP. The interstitial fibrosis was relatively diffuse, it was of variable degree, alveolar 
architecture was preserved and there was mild to moderate interstitial inflammation (Fig. 
13B compared with Figs 16A and C). In another seven dogs, additional patchy areas of 
honeycombing, comparable to UIP, were seen (Fig. 13D compared with Fig. 16B). The 
remaining four WHWTs with CIPF had multifocal accentuation of fibrosis without 
architectural distortion or honeycombing.  
No fibroblast foci were detected in WHWTs with CIPF. Fibroblast foci are seen in 
human UIP (Fig. 16D). The alveolar epithelial lesions were more diffuse and prominent in 
the WHWTs, but comparable in morphology to the epithelial changes in human NSIP. The 
presence of bronchiolar metaplasia of peribronchiolar fibrotic alveolar septa was a dominant 
feature of CIPF in WHWTs and in human UIP, but not prominent in human NSIP. 
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Table 9 Comparison between the main histological criteria required for the diagnoses of  
                   UIP or NSIP in humans and the findings in CIPF in WHWTs. 
Criteria  UIP CIPF NSIP  
(fibrosing) 
Pattern  Patchy, subpleural  or paraseptal 
Diffuse with subpleural/ 
peribronchiolar accentuation Relatively diffuse 
Interstitial fibrosis  Marked, distorting, replacing alveolar tissue 
Mild to marked, not 
obliterating alveolar 
architecture 
Variable degree 
Honeycombing  Yes Yes Not characteristic 
Fibroblastic foci  Yes No Absent or inconspicuous 
Interstitial 
inflammation  Minimal, mild Mild to moderate Mild to moderate 
SM hyperplasia  Yes Yes Not characteristic 
PCII  Hyperplasia Hyperplasia, atypia Hyperplasia in areas of inflammation 
Bronchiolar     
epithelium 
Bronchiolar metaplasia 
of alveolar epithelium 
Bronchiolar metaplasia of     
alveolar epithelium Not recorded 
CIPF, canine idiopathic pulmonary fibrosis; NSIP, nonspecific interstitial pneumonia; PCII, type II 
pneumocyte; SM, smooth muscle; UIP, usual interstitial pneumonia; WHWT, West Highland white terrier. 
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Figure 16 Characteristic lesions of human nonspecific interstitial pneumonia (NSIP) and human 
usual interstitial pneumonia (UIP). (A) Diffuse interstitial fibrosis pattern of NSIP. 
HE. Bar, 1 mm. (B) A subpleural area of severe distorting fibrosis in UIP. HE. Bar, 1 
mm. (C) Temporally homogenous interstitial fibrosis in NSIP. Masson’s trichrome. 
Bar, 200 μm. (D) Temporally heterogeneous fibrosis, with fibroblast foci (asterisk) in 
UIP. Masson’s trichrome. Bar, 1 mm. The images are taken from the publication IV. 
  
 6   DISCUSSION 
6.1   CIPF – CLINICAL DISEASE 
Our goal for the study was to further define the clinicopathological and diagnostic features 
in dogs with CIPF. The study was prospective and included a control group of healthy 
WHWTs. In this thesis summary, the results for 15 dogs with CIPF are presented, which is 
three more than in Study I. All the dogs with CIPF had histopathological confirmation of 
the diagnosis.  
The signalment, clinical signs and the findings from physical examinations of the dogs 
in our study with CIPF were in line with those reported previously (Corcoran et al., 1999a). 
The affected dogs had a mean age of 12 years, and no predisposition for sex was detected. 
The mean duration of clinical signs was 14 months, but it varied considerably (range 2-29 
months). The most common clinical sign was the combination of cough and exercise 
intolerance, but not all the dogs coughed. The reason for the cough in CIPF is unclear. The 
bronchial changes present in many CIPF dogs may contribute to the cough, but are not likely 
to be the only explanation. We also detected bronchial changes in dogs which did not cough 
and, on the other hand, in one coughing dog the airway changes were mild, consisting only 
of mucosal irregularity and grade I tracheal collapse. Human patients with IPF have an 
enhanced cough reflex sensitivity that is hypothesised to be due to upregulation of the 
sensory nerves of the respiratory tract (Hope-Gill et al., 2003). It is unknown whether this 
also exists in dogs.  
Bilateral, inspiratory Velcro crackles were heard in auscultation in 12 of the 15 dogs 
with CIPF, but in none of the healthy controls. This strengthens the previous conclusion that 
Velcro crackles are associated with CIPF (Corcoran et al., 1999a; Lobetti et al., 2001) as 
they are with human IPF (Raghu et al., 2011). In human patients, Velcro crackles can be the 
first sign of IPF and can help in detecting the disease early (Cottin and Cordier, 2012). 
Interestingly in this study, the most severely affected dog was one of the three in which 
Velcro crackles were not heard. Our finding suggests that an absence of Velcro crackles 
cannot be used to rule out even severe CIPF. An explanation for the absence of the crackles 
could be the shallow tachypnoeic breathing present in the severely affected dog. In humans, 
slow breathing from near-residual lung volume helps in detecting the sound (Kraman, 
1986). Since regulation of the breathing pattern in dogs is not possible in the same way as 
in humans, inducing deep breaths by temporarily closing the nostrils could be used to help 
the detection of crackles. 
As we expected hypoxemia to be the key clinical consequence of CIPF, we quantified 
the degree of hypoxemia in our dogs affected by the disease. Arterial blood gas analysis 
revealed surprisingly low PaO2 and high P(A-a)O2 values in CIPF dogs considering that 
most dogs were bright and alert. The slow progression of the disease makes it possible for 
the dogs to become accustomed to the lowering oxygen values. Retention of PaCO2 was not 
detected in any of the dogs. These findings are in line with human IPF: the average patient 
is hypoxemic at rest, P(A-a)O2 is almost always abnormal and alveolar hypoventilation 
leading to hypercapnia is rare (Crystal et al., 1976; Nava and Rubini, 1999).  
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CIPF was not associated with changes in serum biochemistry or haematology. Only one 
of our CIPF dogs had a haematocrit above the reference range (61%). The dog was not 
dehydrated, it had a PaO2 of 42 mmHg and it had had clinical signs for a year. An increase 
in haematocrit (59%) was also noted in one of the control dogs. The lack of polycythaemia 
in the other dogs with CIPF is an interesting finding. In humans, polycythaemia is not linked 
to IPF as it is to other chronic hypoxemic diseases. The reason for this is not known (Crystal 
et al., 1976; American Thoracic Society, European Respiratory Society, 2000). To our 
knowledge, the only previously reported polycythaemic CIPF dogs were two young 
Staffordshire bull terriers (haematocrit 71% and 72%) in the study of Lobetti et al (2001). 
These findings suggest that despite suffering from chronic hypoxemia, polycythaemia is not 
commonly observed in WHWTs with CIPF.   
In accordance to previous reports (Corcoran et al., 1999a; Johnson et al., 2005), 
bronchointerstitial lung pattern was the most commonly detected change in thoracic 
radiographs in our dogs with CIPF. These radiographic signs associated with CIPF are 
nonspecific. We also observed moderate to severe bronchointerstitial lung pattern in all dogs 
with CB, and approximately half the dogs with EBP had both bronchial and interstitial 
opacities. Alveolar opacities were seen in three CIPF dogs. In one, HRCT was performed 
and no such finding could be observed. This suggests that alveolar opacity in radiographs 
might be at least partly explained by poor inflation of the lung. In thoracic radiographs of 
human patients with IPF, honeycombing becomes evident when disease progresses (Crystal 
et al., 1976). To our knowledge, honeycomb change has not been described in radiographs 
of dogs with CIPF.  
 HRCT is a much more sensitive imaging method for detecting changes in the lung 
parenchyma than thoracic radiographs. HRCT is gaining more and more ground in 
veterinary medicine and is crucial in diagnosing human IPF (Raghu et al., 2011). The most 
common finding in our dogs with CIPF was GGO, described as a hazy increase in overall 
lung density. Similar to the findings of Johnson et al. (2005), GGO was visible in all our 
dogs with CIPF investigated by HRCT. This contrasts to HRCT findings of human IPF. In 
humans, the presence of GGO points more towards an alternative diagnosis, such as NSIP, 
whereas honeycombing, traction bronchiectasis, coarse reticulation and architectural 
distortion are characteristic of IPF (Gotway et al., 2007). Here, reticular opacities were seen 
in all dogs with CIPF but in none of the controls. Traction bronchiectasis was present in five 
and honeycombing in two dogs. Johnson et al. (2005) suggested that traction bronchiectasis 
and honeycombing appear when CIPF is already severe, however, in our study both findings 
were present in the least affected dog.  
In bronchoscopy, we detected signs of airway involvement in all CIPF dogs, CB dogs 
and EBP dogs. A variety of changes was described in each group. This indicates that 
bronchoscopic findings commonly associated with airway disease cannot be used to rule 
out CIPF. Mucosal irregularity, which was present in all dogs with CIPF, and approximately 
every second dog with CB and EBP, was also noted in the majority of the healthy control 
WHWTs. It could be at least partly explained by the old age of the dogs (Mercier et al., 
2011). An increased amount of bronchial mucus is one of the key features of CB (Pirie and 
Wheeldon, 1976) and commonly reported in EBP (Rajamäki et al., 2002). It seemed to be 
more often a concern in dogs with CB (detected in 14 of the 22 dogs) and dogs with EBP 
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(12 of 15 dogs) than in dogs with CIPF (3 of 9 dogs). Instead, tracheal collapse was more 
commonly observed in WHWTs with CIPF (6 of 9 dogs) than in other dogs (3 of 22 CB 
dogs, none of the EBP dogs). Corcoran et al. (2011) also reported that tracheal collapse was 
common in WHWTs with CIPF. This might contribute to the clinical presentation of CIPF 
dogs, at least if the collapse is severe, however, the true significance of this finding and its 
possible relationship, if any, to the underlying ILD is unclear. Nevertheless, we also detected 
mild tracheal collapse in three of the nine healthy control WHWTs. The WHWT has not 
been previously reported to be among the breeds predisposed to tracheal collapse (Della 
Maggiore, 2014). Our findings indicate that airway changes are common in dogs with CIPF. 
We do not know whether the changes occur secondarily to CIPF or as an individual 
phenomenon. Despite the degree of airway changes, all our CIPF dogs had a similar 
histopathologic picture of interstitial fibrosis.   
Previously, mainly normal to moderately increased BALF cellularities have been 
described in dogs with CIPF (Corcoran et al., 1999a; Corcoran et al., 2011). However, 
BALF cellularities have not been compared between dogs with CIPF and healthy dogs. We 
elected to have a healthy control group of the same breed in order to exclude the possibility 
that breed would influence our results. So far, no studies comparing BALF cellularities 
between different dog breeds have been conducted. In our study, the dogs with CIPF had an 
increase in BALF TCC due to increased numbers of macrophages, neutrophils and mast 
cells. On histopathological examination of lung tissue, intra-alveolar accumulation of 
macrophages was evident in many dogs, reflecting the role of macrophages in CIPF 
pathology. The increase in TCC is likely a consequence of the ILD rather than solely a 
secondary bronchial reaction to coughing, as it was also increased in those dogs that had not 
been coughing. In Study I, the only change in relative differential cell counts was detected 
in the lymphocyte percentage, which was lower in dogs with CIPF than in healthy WHWTs. 
As we included more dogs in the thesis summary than in Study I, changes in eosinophilic 
percentage (lower in CIPF than in healthy) and mast cell percentage (higher in CIPF than 
in healthy) also reached statistical significance.  We correlated BALF TCC, individual and 
differential cell counts with PaO2 and detected only weak correlations, which may not be of 
clinical value. In human IPF, TCC is increased and BALF neutrophilia and mild or moderate 
eosinophilia are described. Lack of lymphocytosis supports the IPF diagnosis. In NSIP, 
BALF lymphocytosis is typical (Domagała-Kulawik et al., 2012; Meyer et al., 2012).  
6.2   CIPF BIOMARKERS 
Given the challenges to diagnosing CIPF in dogs, one of the aims of this thesis was to 
identify non-invasive biomarkers of fibrosis which could help in detecting the disease.  In 
this thesis we investigated whether ET-1 or PIIINP could be useful in differentiating CIPF 
from other chronic respiratory diseases in dogs.  We measured ET-1 and PIIINP 
concentration in both serum and BALF of dogs with CIPF, CB, EBP as well as in two groups 
of healthy control dogs.  
Obtaining BALF requires anaesthesia, which cannot be performed on dogs with very 
advanced lung disease. The advantage of a BALF marker is, however, that it may provide a 
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more accurate indication of lung disease than serum markers, which are more likely 
influenced by various processes unrelated to pulmonary pathology. A serum biomarker is 
easily obtained and therefore more practical to use. 
 
6.2.1   ENDOTHELIN-1 
Serum ET-1 concentration was elevated in dogs with CIPF when compared with dogs with 
CB, EBP or healthy dogs. Additionally, BALF ET-1 was measured in dogs with CIPF and 
CB to study whether it could differentiate these two diseases. In BALF, ET-1 concentration 
was above the detection threshold of the test only in dogs with CIPF. These findings are in 
agreement with findings in human IPF in which elevated ET-1 concentration is found in 
plasma, BALF and lung tissue (Giaid et al., 1993; Sofia et al., 1993; Uguccioni et al., 1995). 
ET-1 has a well established role in the fibrogenesis of human IPF. Among other things, it 
acts synergistically with other fibrosis mediators, such as TGF-β, and participates in the 
recruitment of fibroproliferative cells, induces production of collagen and reduces 
collagenase activity; events which ultimately lead to excess collagen deposition in the lung 
(Swigris and Brown, 2010). Our results suggest that ET-1 may also be implicated in the 
pathogenesis of CIPF.  
In humans, ET-1 concentration is known to increase with age (Komatsumoto and Nara, 
1995). As our dogs with CIPF were older than dogs with CB, EBP or healthy dogs, we 
wanted to investigate the possible influence of age on the ET-1 concentration. A covariate 
analysis did not show that age would affect ET-1 values. This is in line with a previous study 
of 76 healthy dogs in which plasma ET-1 concentration was not found to correlate with age 
(Tessier-Vetzel et al., 2006). 
We included both healthy WHWTs and healthy beagles as healthy control dogs. There 
was no difference in serum ET-1 concentration between these two groups, excluding a 
possible breed influence on ET-1 results. 
No elevation was detected in serum ET-1 concentration in dogs with CB or EBP when 
compared with healthy dogs. Previously, high plasma ET-1 concentration was detected in a 
group of dogs with respiratory disease when compared to healthy dogs. Dogs with severe 
respiratory disease had higher ET-1 values than dogs with occasional coughing, however, 
the study did not separate the different respiratory diseases (Tessier-Vetzel et al., 2006). In 
humans, in addition to IPF, an increase in ET-1 is also associated with other lung diseases. 
In asthma, serum and BALF ET-1 concentration is elevated and ET-1 is thought to 
contribute to bronchoconstriction typical for the disease (Sofia et al., 1993; Gawlik et al., 
2006). Asthma is not recognised as such in dogs, but EBP shares some of its features, such 
as airway eosinophilia and T helper 2 dominant immune response (Clercx and Peeters, 
2007). It seems that ET-1 does not have a similar importance in the pathology of EBP as it 
has in human asthma. In human patients with COPD, it has been suggested that ET-1 is 
involved in airway obstruction and the exaggerated sputum production characteristic of the 
disease (Roland et al., 2001). Both elevated and normal ET-1 levels have been reported in 
human patients with COPD, however (Chalmers et al., 1999; Reichenberger et al., 2001; 
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Roland et al., 2001). Canine CB is often compared to human COPD, although these two 
diseases can have quite different clinical pictures. ET-1 appears not to be implicated in the 
pathogenesis of CB in dogs.  
A ROC curve analysis confirmed that serum ET-1 concentration can be used to 
differentiate CIPF from CB with good accuracy. The optimal cut off value yielded an 
excellent sensitivity of 100% and a good specificity of 85%. Previous studies have shown 
that overt heart failure and PH increase ET-1 concentration in dogs (Prošek et al., 2004; 
Tessier-Vetzel et al., 2006), and therefore, an echocardiographic examination aimed 
specifically at detecting PH should be performed if ET-1 measurements are to be used as an 
adjunctive method for diagnosing CIPF.  
ET-1 being measurable from serum is a clear advantage for its use as a biomarker of 
CIPF, however, we detected no correlation between serum ET-1 concentration and the 
severity or duration of CIPF. In addition, Lilja-Maula et al. (2014a) showed that ET-1 has 
no prognostic value in CIPF. ET-1 could therefore be useful as a diagnostic biomarker for 
CIPF, but not used to monitor the progression of the disease.  
6.2.2   PIIINP 
Serum PIIINP concentration does not seem to be useful in assessing lung diseases in dogs. 
There was no difference in serum PIIINP concentration between dogs with CIPF, CB, EBP 
or healthy dogs, nor did it correlate with BALF PIIINP concentration. This in accordance 
with an earlier study conducted in dogs suffering from chronic bronchopneumopathy 
(Schuller et al., 2006), but contradicts some studies in humans (Kirk et al., 1984; Low et al., 
1992, Harrison et al., 1993; Lammi et al, 1999). 
CIPF instead caused an elevation in BALF PIIINP concentration. This agrees with 
findings in human IPF (Bjermer et al., 1989; Harrison et al., 1993; Hiwatari et al., 1997; 
Lammi et al., 1999). High BALF PIIINP is thought to signify active collagen type III 
synthesis in the lung, and therefore, BALF PIIINP could be a marker of disease activity 
rather than indicate the severity of the disease (Lammi et al., 1999).  
We used oxygen values as markers of disease severity in our CIPF dogs, as did Lilja-
Maula et al. (2014a) in their study, and investigated whether BALF PIIINP correlated with 
these or with the duration of clinical signs. No correlation was detected. Studies in which 
BALF PIIINP was correlated with the severity of IPF in humans have offered variable 
results, however, high BALF PIIINP concentration has repeatedly been associated with 
more rapid disease progression and poorer prognosis in human IPF (Bjermer et al., 1989; 
Low et al., 1992; Lammi et al., 1999). No studies have evaluated the use of BALF PIIINP 
concentration as a prognostic marker in dogs with CIPF.   
Elevated BALF PIIINP concentration is not specific to CIPF. In addition to dogs with 
CIPF, dogs with EBP also had higher BALF PIIINP concentration than dogs with CB or 
healthy dogs in our study. This finding confirms the results of a previous study, in which an 
elevation of BALF PIIINP was detected in 15 dogs with chronic bronchopneumopathy, 13 
of which had EBP (Schuller et al., 2006). It is likely that elevated BALF PIIINP 
concentration is caused by secondary fibrotic changes due to chronic eosinophilic 
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inflammation of the lungs. Based on the histology of bronchial biopsies, fibrotic changes 
are reported to accompany severe bronchial inflammation in EBP dogs (Clercx et al., 2000).  
Although BALF PIIINP is elevated also in dogs with EBP, it does not raise a concern for 
its use as a biomarker of CIPF. CIPF can be easily differentiated from EBP by BALF 
cytology analysis: marked eosinophilia is a requirement for EBP diagnosis but is not 
characteristic of CIPF.  
Differentiating CIPF from CB is a greater challenge. Both diseases share clinical and 
diagnostic features, and bronchoscopic findings suggestive of CB also occur in dogs with 
CIPF. Interestingly, BALF PIIINP concentration was not elevated in dogs with CB in our 
study. This finding agrees with a previous study in which BALF PIIINP concentration did 
not rise after experimentally inducing bronchial inflammation in dogs (Lonneux et al., 
2009). In humans, levels of PIIINP are increased in airways of patients with COPD (Harju 
et al., 2010). We further assessed the ability of BALF PIIINP to differentiate CIPF from CB 
by using ROC curve analysis. The AUC of 0.81 suggests that BALF PIIINP could be used 
to differentiate these two diseases with moderate accuracy (Swets, 1988). Investigating the 
BALF PIIINP concentration could therefore be a useful addition to other diagnostic tests 
for differentiating these two diseases, although PIIINP being elevated only in BALF and 
not in serum is a disadvantage which makes it applicable only in limited circumstances.  
6.3   CIPF – HISTOPATHOLOGICAL ASPECTS 
The histopathological features of CIPF have been unclear. Consequently, it has not been 
known whether there is resemblance between CIPF and human disease and if so, to what 
extent. Previous studies of CIPF have included only a limited number of dogs, and perhaps 
for this reason the results have been contradictory. We performed a comprehensive study of 
the histopathological features of CIPF by investigating lung samples from 18 WHWTs with 
the disease using routine staining, collagen staining, and immunohistochemical techniques, 
and provided a comparison with human UIP and NSIP.  
Two different kinds of interstitial fibrosis were detected in WHWTs with CIPF. A 
pattern of diffuse and mature homogenous fibrosis was present in all dogs, and a 
multifocally accentuated pattern of severe, less mature fibrosis was also detected in the 
majority of the dogs. The diffuse fibrosis varied from mild to moderate in severity and was 
equally distributed throughout the lung. It did not lead to architectural distortion. A similar 
type of interstitial fibrosis was described in six dogs with CIPF by Norris et al. (2005). This 
diffuse, mature and uniform-appearing interstitial fibrosis, detected in all WHWTs in our 
study, closely resembles the fibrosis pattern of human NSIP (American Thoracic Society, 
European Respiratory Society, 2002; Katzenstein et al., 2008).  As the diffuse fibrosis was 
mature and present in all dogs, it might represent an early lesion of CIPF. It is not known 
what triggers the formation of diffuse fibrosis in WHWTs. Interstitial fibrosis with 
concentric deposition of collagen around small vessels, as detected here and also by Norris 
et al. (2005), can occur as a consequence of PH. PH is a common complication of CIPF and 
we suspected it in several dogs, however, it is not likely to be the only reason, as we did not 
consistently find other histopathological findings indicating PH, such as pulmonary arterial 
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hypertrophy (Van Vleet and Ferrans, 2007). In humans, the histopathological pattern of 
NSIP is commonly seen as a lung manifestation of systemic connective tissue diseases 
(Travis et al., 2013). A disease with systemic increase in collagen deposition has not been 
described in dogs. TGF-β, a key mediator of fibrosis in humans, was recently shown to be 
involved in the fibrogenesis of CIPF (Lilja-Maula et al., 2014c). An increased serum 
concentration of TGF-β, detected both in healthy and sick WHWTs, could be one of the 
explanatory factors predisposing the dogs to fibrosis (Krafft et al., 2014).  
In addition to diffuse fibrosis, we observed multifocal areas of more severe, more 
cellular and less mature fibrosis. These areas were accompanied by profound alveolar 
epithelial and luminal changes, smooth muscle hyperplasia and occasional honeycombing. 
This change bears close resemblance to human UIP (American Thoracic Society, European 
Respiratory Society, 2002; Raghu et al., 2011). Multifocally accentuated fibrosis was also 
described in dogs with CIPF by Corcoran et al. (1999a) and Erikson et al. (2009). In our 
study, the areas of more severe fibrosis were located either around the bronchioli or under 
the pleura. In human UIP the areas of architectural distortion appear patchy and are located 
subpleurally and paraseptally, but not peribronchiolarly (Katzenstein et al., 2008). 
Paraseptal location refers to sites near the interlobular connective tissue septae which are 
absent in canine lungs. One explanation for the subpleural location of UIP changes might 
be stretching of the distal lung due to reduced lung compliance (Günther et al., 2012). 
Hunninghake and Schwarz (2007) suggested another explanation by speculating that the 
peripheral parts might be more accessible to injury or less prone to normal repair. It remains 
to be investigated whether these hypotheses are true in dogs. The peribronchiolar location 
of areas of accentuated fibrosis indicates that an additional inhaled etiological factor could 
be involved in the pathogenesis of CIPF.  
PCII hyperplasia and atypia were a consistent finding in CIPF based on our results. This 
is in line with changes characteristic of UIP and may indicate a repetitive damage to the 
alveolar epithelium. In UIP, chronic injury to the alveolar epithelium and excessive 
apoptosis of alveolar epithelial cells may lead to exhaustion of the alveolar epithelial 
regenerative potential. This in turn could cause alveolar epithelial cells to lose control over 
mesenchymal cells leading to fibroblast proliferation and an accumulation of collagen 
(Günther et al., 2012).  
In addition to PCII changes, the majority of the dogs with CIPF in our study had 
bronchiolar metaplasia of the alveolar epithelium. This finding is also described in UIP. 
Bronchiolisation of the alveoli could arise from migration and differentiation of bronchial 
progenitor cells into the alveoli in an attempt to repair the damaged alveolar epithelium 
(Betsuyaku et al., 2000). Recently, in addition to the alveolar epithelium, bronchiolar 
epithelium of the distal airways has also been suggested to contribute to the pathogenesis of 
UIP in humans. This idea is supported by abnormal bronchiolar proliferation present in UIP, 
other histological evidence of small airway involvement and recent genetic studies showing 
mucin 5B gene promoter polymorphism as a risk factor for IPF (Chilosi et al., 2002; Figueira 
de Mello et al., 2010; Fingerlin et al., 2013; Seibold et al., 2013).   
Fibroblast foci, a hallmark of human UIP, were not seen in any of the WHWTs with 
CIPF. In UIP, fibroblast foci signify areas of active fibrosis and temporal heterogeneity of 
the fibrosis process, in NSIP the fibroblast foci are usually absent (Katzenstein et al., 2008). 
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It is not known, however, why fibroblasts and myofibroblasts organise into such foci in UIP. 
Myofibroblasts are active cells which secrete excess amounts of extracellular matrix 
components and play an important role in creating a profibrotic milieu (King Jr et al., 
2011b). Interestingly, we could identify scattered myofibroblasts in the interstitium in areas 
of more cellular fibrosis. This finding suggests that although not organised in specific 
bundles, myofibroblasts also participate in fibrogenesis in CIPF. 
In addition to proliferating fibroblasts and the production of collagen, other mechanisms 
may also contribute to the development of interstitial fibrosis. Katzenstein (1985) described 
a fibrosis process in which intra-alveolar exudates were incorporated into the alveolar wall. 
This was found to take place in lungs of patients with acute interstitial pneumonia 
characterised histopathologically by DAD. PCII cells proliferated on top of intraluminal 
cellular debris located near the denuded alveolar basement membrane (Katzenstein, 1985). 
We detected DAD and organising fibrosis along the alveolar luminal lining in several dogs 
with CIPF. Areas of DAD co-localised within areas of more severe fibrosis. We suggest that 
incorporation of alveolar exudates into alveolar septa could also contribute to the 
development of fibrosis in dogs with CIPF.  
We did not detect severe fibrotic scarring obliterating larger areas of the alveolar 
architecture. Even in the most affected areas, alveolar spaces could be identified between 
severely fibrotic alveolar walls. This differs from human UIP, in which profound scarring 
can lead to complete loss of alveolar structural design (Katzenstein et al., 2008). 
Based on our findings, inflammation is not prominent in CIPF. We detected only mild 
to moderate lymphoplasmacytic interstitial inflammation in our dogs. Norris et al. (2005) 
described an inflammation of the same cell type but of more varying degree. Inflammation 
is not a prominent feature of UIP either. Our finding supports the hypothesis that ongoing 
inflammation is an unlikely cause for the progressive fibrosis.  
Alveolar proteinosis was common in WHWTs with CIPF.  Alveolar proteinosis results 
when surfactant accumulates into the alveolar lumens. It can result from either increased 
production or modification of surfactant by PCII cells or decreased surfactant clearance by 
alveolar macrophages. We speculate that both the PCII cells, which were morphologically 
abnormal, as well as the intra-alveolar macrophages which we could frequently detect, could 
be involved in the development of alveolar proteinosis in CIPF. As a primary disease, 
alveolar proteinosis is rare and only a few case reports have been published involving dogs 
(Jefferies et al., 1987; Silverstein et al., 2000; Cummings et al., 2013). Alveolar proteinosis 
is a chronic progressive ILD and can be considered one of the differential diagnoses of 
CIPF, however, affected dogs have been considerably younger. Alveolar proteinosis can 
occur secondarily to various lung disorders, and it has been associated with the inhalation 
of irritant substances in humans and in experimental animal models (Borie et al., 2011). 
This could support the hypothesis that an inhaled irritant would be involved in the 
pathogenesis of CIPF. In human patients with alveolar proteinosis, interstitial fibrosis can 
sometimes be detected in histopathology (Arbiser et al., 2003). Arbiser et al. suggested that 
an accumulation of surfactant could promote fibrosis. It is not known whether it contributes 
to the diffuse interstitial fibrosis typical of CIPF. 
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6.4   LIMITATIONS OF THE STUDY 
We recruited 15 dogs with CIPF into our studies. The small number of dogs decreased the 
power of our statistical analyses. The number of CIPF dogs undergoing HRCT (7 dogs) was 
especially small. This should be taken into account when interpreting HRCT findings.  
Although CIPF can be considered a disease of WHWTs, we decided to add one Scottish 
terrier to our study population. It can be speculated whether this brought additional value 
by increasing the case number or whether it was confusing. The results of the 
clinicopathological, diagnostic imaging and biomarker examinations obtained from the 
Scottish terrier were in line with those of the WHWTs with CIPF participating in the study. 
It is not known whether CIPF is exactly the same disease in different breeds of dogs. 
Because CIPF is not common, recruiting cases for research is challenging. Scottish terriers 
and WHWTs originate from the same Scottish dog ancestors and are therefore likely to be 
closely related. We argue that adding a Scottish terrier adds as much value to our studies as 
adding a WHWT. 
We were able to include a control group of 14 healthy WHWTs in our studies. To 
confirm their health status, the majority of the dogs underwent very thorough examinations 
including arterial blood gas analysis, HRCT, bronchoscopy and BAL, and showed no signs 
of lung disease, however, as histopathology was only obtained from one of the dogs at a 
later date, a subclinical respiratory disease cannot be completely excluded. Whether a 
subclinical respiratory disease would explain the overlap in BALF PIIINP concentration 
between CIPF and healthy dogs, can only be speculated. 
PH is common in dogs with CIPF, affecting more than 40% of the diseased dogs 
(Schober and Baade, 2006). We suspected it in 7 of the 13 dogs undergoing 
echocardiography. Those dogs showed right-sided ventricular dilatation and hypertrophy 
without primary cardiac diseases explaining the changes, however, as the pressure gradients 
across tricuspid valve were not calculated, we were not able to confirm the presence of PH 
in our dogs. Concurrent PH can significantly increase ET-1 concentration (Tessier-Vetzel 
et al., 2006). We therefore cannot exclude an effect from PH on the increased ET-1 results 
obtained from our dogs with CIPF. Serum ET-1 concentration was not different between 
the dogs suspected to have PH and those with normal echocardiographic examination, 
however. The dog with the highest serum ET-1 concentration did not have any findings 
indicating PH. 
This study was conducted as a bicentre study. Examinations took place at the Veterinary 
Teaching Hospitals of the Universities of Helsinki and Liège. For this reason, we used two 
different BAL collection protocols. In one protocol, a weight-adjusted amount of lavage 
fluid was used (2 mL/kg divided in two aliquots), and in the other protocol, a fixed amount 
of lavage fluid was instilled (60 ml divided into three aliquots). This might have affected 
the dilution factor and the amount of recovered epithelial lining fluid. Melamies et al. 
showed (2011) that the weight-adjusted protocol leads to less variance in epithelial lining 
fluid recovery than a fixed-amount technique, however, the difference was small. It is 
unlikely that the different BALF protocols would have had a significant effect on BALF 
PIIINP or BALF ET-1 concentration. 
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One of our aims was to study the distribution of the histopathological lesions in WHWTs 
with CIPF. This information is important when lungs are sampled for histopathological 
examination in clinical practice. Unfortunately, we only had lobe specific lung samples from 
nine WHWTs with CIPF. We noticed that in dogs with mild diffuse fibrosis, the multifocal 
areas were more often located in the caudal than in the other lung lobes, but in dogs with 
moderate diffuse fibrosis, the fibrosis accentuation areas were equally seen in cranial and 
caudal lung lobes. The small number of lobe specific samples impeded us from making 
stronger conclusions.  
For collagen and IHC staining, we selected only a single site of lung from each WHWT 
with CIPF. The site with the most severe lesions was chosen, which we expected to best 
correspond to lesions in human UIP. Optimally, several sites would have been evaluated. 
Therefore, it can be questioned whether choosing only one lung site for further staining 
influenced the comparison between CIPF and human UIP and NSIP. We investigated the 
maturity of fibrosis by collagen staining. By IHC staining we investigated qualitatively 
whether PCII hyperplasia, SM hyperplasia and bronchiolar metaplasia were present in 
affected canine lung, as these changes are characterized in human UIP. For general 
comparison between the canine and human diseases, the whole histologic picture from 
different HE stained lung sections, consisting of the pattern and degree of interstitial 
fibrosis, presence of honeycombing and inflammation, and distribution of lesions, was taken 
into account.  
Only one of the three dogs we used as healthy controls in the histopathological study 
was of similar age to the diseased dogs. Based on this, we were not able to make any 
observations about possible age-related changes in the lung tissue.  
6.5   FURTHER RESEARCH 
For a long time CIPF has been considered a rare disease in dogs, but is this an outdated 
assumption? As veterinarians and dog owners become more familiar with the disease, it 
seems that CIPF is diagnosed more and more often, at least in Finland. It is worrying that 
in recent decades the incidence of human IPF has been rising (Navaratnam et al., 2011). In 
dogs, there are no estimates of the prevalence and incidence of CIPF. An epidemiological 
study would help us understand how widespread the problem we are dealing with is, how 
frequent CIPF is among WHWTs. Accurate answers are desired by the owners of the 
WHWTs and all enthusiasts of the breed. There is incentive for us to learn whether CIPF is 
an emerging disease. If this proves to be true, we should hurry to search for the reason.   
Dogs with CIPF are commonly treated with corticosteroids despite there being no 
evidence to support their use. To date, no treatment trials have been performed on dogs with 
CIPF. In humans, corticosteroid therapy is no longer used to treat IPF, but it has a role in 
treating patients with NSIP (Kim et al., 2006; Raghu et al., 2011). Our study showed that 
dogs with CIPF have histopathological features of both of these human diseases. It would 
be important to know whether dogs truly benefit from corticosteroid treatment as do many 
people with NSIP, or whether the treatment does more harm than good. Investigating the 
potential effect of corticosteroid therapy on clinical signs and findings, arterial oxygenation, 
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HRCT features and on outcome might give us new insight into the pathophysiology of the 
disease. The interpretation of corticosteroid treatment trial results on CIPF, however, are 
likely complicated by corticosteroids potentially having an effect on the concomitant 
tracheal and bronchial problems of the CIPF dogs. 
CIPF is a disease of WHWTs. Reports of the disease in other breeds of dogs are scarce. 
Lobetti et al. (2001) described the disease in Staffordshire bull terriers which were 
considerably younger than WHWTs usually are when diagnosed with CIPF. A question 
arises as to whether CIPF is the exact same disease across dog breeds. Could there be 
differences in CIPF of a WHWT and CIPF of a dog of another breed? Perhaps there is a 
variety of fibrotic ILDs affecting dogs, CIPF being only the tip of an iceberg. A combined 
clinical and histopathological study looking in detail at the patterns of fibrosis and clinical 
findings could answer these questions. As CIPF is seldom found in dogs other than 
WHWTs, a multicentre approach could be useful in obtaining adequate cases for study. 
It is very challenging to try to diagnose CIPF at an early stage, before a dog shows any 
clinical signs. HRCT is probably one of the most sensitive means to detect subtle changes 
in the lung. New, faster CT scanners make this imaging method more feasible, as 
anaesthesia may not be needed for the procedure. HRCT scans might also be a way to 
monitor disease progression. We lack understanding about the histopathologic 
correspondence of the HRCT changes associated with CIPF, however. In humans, GGO, 
for example, might reflect different pathologic processes including inflammation or fibrosis 
beyond the resolution of the CT (Gotway et al., 2007). Which one is it in CIPF? Are the 
areas of GGO evolving to honeycombing and traction bronchiectasis? To make the most of 
the HRCT images, a study comparing the HRCT changes and the histopathologic 
appearance of those exact areas at the same time point would be of great value.  
As our studies indicated, biomarkers can be useful aids in diagnosing CIPF. In addition 
to being part of the diagnostic puzzle, biomarkers could offer much more: they could be of 
prognostic value. To take the thought even further, the ideal biomarker would be able to 
predict which individual was going to get the disease and which was going to remain 
healthy. Such a biomarker does not exist, yet. Maybe a combination of various biomarkers 
would prove to be most helpful. There is much research needed in this field. 
Matrix metalloproteinases (MMPs) are a group of proteases which participate in the 
remodelling of lung extracellular matrix (Oikonomidi et al., 2009), a process crucial to the 
development of CIPF. Our pilot study already showed increased MMP-2 and -9 activity in 
dogs with CIPF in comparison to CB (Heikkilä et al., 2011). In addition to these two MMPs, 
other MMPs are also implicated in the pathogenesis of human IPF. MMP-7 has shown 
potential as a biomarker predicting the progression of IPF and correlating with the severity 
of the disease in humans (Rosas et al., 2008; Song et al., 2013). The role of MMP-7 has not 
been studied in dogs with CIPF and it is therefore an obvious candidate for future research.  
Many other aspects of CIPF require further clarification, such as the heritability of CIPF. 
It is likely to be a complex genetic dilemma but it must be resolved. Genetic studies can 
only be successful if the participating WHWTs with CIPF and control WHWTs are correctly 
diagnosed. A correct diagnosis is based on a well established phenotype, both clinically and 
histopathologically. Biomarkers may be of help. Our studies therefore provide a good basis 
on which further studies can build.
 7   CONCLUSIONS 
 
 
1. CIPF affects older WHWTs. The typical clinical sign is the combination of 
cough and exercise intolerance. Abdominal breathing pattern and Velcro 
crackles are often present. Thoracic radiographs show a bronchointerstitial 
lung pattern. CIPF does not induce specific haematological or serum 
biochemical alterations, and leads to significant hypoxemia. CIPF dogs have 
bronchoscopically detectable airway changes, and an increase in BALF TCC. 
On HRCT, GGO appears to be typical of CIPF but reticular changes are also 
noted.  
 
2. Serum ET-1 concentration is elevated in dogs with CIPF in comparison to 
dogs with CB, EBP or healthy dogs. It can be used with good accuracy to 
differentiate between CIPF and CB. BALF ET-1 concentration is elevated in 
CIPF when compared to CB.  CIPF is also associated with an elevated BALF 
PIIINP concentration, which can be used as a marker for differentiating CIPF 
from CB. Dogs with EBP also have high BALF PIIINP values. Serum PIIINP 
cannot be used to detect lung diseases in dogs. 
 
3. CIPF is characterised by two types of interstitial fibrosis: a diffuse and mature  
fibrosis affecting the alveolar walls, and a multifocally accentuated, less 
mature fibrosis. Profound alveolar epithelial and luminal changes and 
occasional honeycombing accompany the areas of more severe fibrosis. 
Fibroblast foci are not a feature, but scattered myofibroblast are present in the 
interstitium. Areas of more severe fibrosis are predominantly located around 
the bronchioli or under the pleura. Based on these results, we conclude that 
CIPF shares features of both human UIP and NSIP. 
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